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Adult multipotent stromal cells (MSCs) have become popular within veterinary 
sciences for direct administration and tissue regeneration due to their differentiation, 
trophic and immunosuppressive properties.  However, current isolation and expansion 
techniques provide a heterogeneous population with other types of cells, which may 
affect the efficiency and efficacy of treatments.  The progenitor properties and 
function need to be further evaluated in vitro prior to in vivo application.  The first 
part of this dissertation was to identify the optimal MSC source for general canine 
orthopedic applications such as intra-articular injection and joint tissue regeneration.  
Based on side-by-side comparisons of cell doublings, colony forming unit frequencies, 
target gene expression and immunophenotype, the infrapatellar fat pad (IFP) had 
MSCs with higher yield, expansion, multipotentiality and progenitor 
immunophenotypes than joint capsular and cranial cruciate ligament (CrCL) 
synovium.  The second part of this dissertation was designed for optimization of 
isolation and in vitro expansion techniques for feline adipose-derived MSCs (ASCs).  
A new method was designed with which a therapeutic dose of ASCs (7 x 106 cells/kg) 
was available within 3 cell passages from epididymal adipose excised during 
castration.  The isolated ASCs maintained their progenitor properties after 
cryopreservation.  Feline-specific culture medium to induce adipogenesis, 
osteogenesis and chondrogenesis was also developed in the study for later application 
in feline tissue regeneration studies.  The third part of this dissertation to apply canine 
IFP ASCs for CrCL regeneration.  A custom perfusion bioreactor was designed and 
built to accommodate canine CrCL templates on which to grow viable grafts with IFP 
ASCs.  Culture medium and template composition and design were optimized to 




templates cultured in stromal (basal) medium those cultured in induction medium had 
enhanced collagen deposition, procollagen synthesis and ligament specific gene 
mRNA levels.  The results from this investigation confirm the feasibility of growing 
new canine CrCLs from ASCs in the laboratory for implantation to treat dogs with 
CrCL disruption.  Overall, the investigations in this dissertation provide vital 
translational information for canine and feline MSC therapies, and may contribute to 




















CHAPTER 1. STROMAL CELL RESEARCH  
1.1 Stromal Cell Introduction 
1.1.1 Multipotent Stromal Cell Nomenclature 
Stromal (Stem) cells are functional units that are capable of self-renewal through 
mitotic cell division and have the potential to differentiate into different cell lineages.  
The term stromal was first proposed by Edmund Beecher Wilson in 1896 [1].  Over 
70 years later, Canadian scientists Ernest A. McCulloch and James E. Till confirmed 
the existence of self-renewing cells from mouse bone marrow [2, 3].  Friedenstein and 
his colleagues then discovered that bone marrow-derived cells were able to 
differentiate towards osteogenesis [4].  The initial adherent cells expanded in vitro 
into round-shaped colonies of fibroblastoid cells or colony forming unit-fibroblasts 
(CFU-f).  During that same time period, several groups found that bone or bone 
extracts formed cartilage or bone after subcutaneous or intramuscular implantation [5-
7].  In the 1970s, bone marrow-derived cells were shown to have proliferative abilities, 
specific phenotypic characteristics and to differentiate into adipocytes, chondrocytes 
and even myoblasts in vitro [8-11].  Additionally, they were capable of differentiating 
into non-mesenchymal lineages such as neurons.  Though differentiated cells did not 
generate action potentials, this confirmed the plasticity of MSCs [12-14].  Caplan 
proposed the name mesenchymal stem cells (MSCs) for the cells isolated from stroma 
based on their ability to differentiate into cells within mesenchymal lineages[15].  
However, there is intense debate over whether or not the cells should be considered 
true stem cells.  As a result, the term “multipotent mesenchymal stromal cells” has 




1.1.2 Multipotent Stromal Cell Definition and Identification 
The term MSC refers to a heterogeneous cell population.  The International Society 
for Cell Therapy defines an MSC as a cell with the following properties: adherence to 
plastic under standard culture conditions; CD73+, CD90+, CD105+, CD34-, CD45-, 
HLA-DR-, CD14- or CD11b-, CD79a- or CD19-; and in vitro osteogenesis, 
adipogenesis and chondrogenesis (demonstrated by staining) [18, 19].  However, 
these criteria are not applied uniformly across species [20].  
So far, MSCs have been isolated from numerous species including humans, 
dogs and cats, and from many tissues including bone marrow, adipose, cartilage and 
synovium [21-25].  Cells derived from different sources show different in vitro 
phenotypic characteristics and proliferation, but they share the ability to differentiate 
into mesenchymal lineages and surface marker expression [26-28].  Variability in cell 
characterization influences the ability to translate uniform MSC-based products into 
clinical practice.  Uniform definitions and quality control standards are needed to 
predict in vivo behavior of implanted cells [29]. 
1.2 Multipotent Stromal Cell Characteristics 
1.2.1 Multipotent Stromal Cell Niche 
The stromal cell niche is the complex, three-dimensional (3D) microenvironment 
where adult stromal cells reside [30, 31].  The interactions between stromal cells with 
the other cells and extra-cellular matrix (ECM) within the niche are complex.  
Paracrine interactions occur though growth factors, chemokines and cytokines, among 
other factors [31].  Cell-cell interactions occur through cell associated proteins like 
cadherins and notch ligands.  Interactions with the ECM are possible with proteins 
like fibronectin, laminin, collagen and proteoglycan.  Other things that contribute to 




properties and architecture.  A combination of genetic expression and environmental 
signals are required for MSCs give up their ‘stemness’ and go through lineage-
specific progenitor division toward terminal differentiation into effector cells [32].  
Reconstruction of a functional niche is a critical component of regenerative medicine. 
1.2.2 Multipotent Stromal Cell and Pericytes 
The exact location and specific role of native MSCs within host tissue is not well 
defined.  There are few reports surrounding in vivo MSC niches with the exception of 
the hair follicle, intestine, synovium and bone marrow [33-36].  In vitro conditions do 
not fully replicate the natural niche, which makes it difficult to study.  Under ex vivo 
culture conditions, MSCs are known to undergo phenotypic alterations that may not 
occur in vivo [23].  The perivascular location has recently been suggested as an MSC 
niche in human [37, 38].  Pericytes, thought to be progenitor cells, are located on the 
abluminal side of small blood vessels, including arterioles, capillaries, and venules in 
multiple human organs, including skeletal muscle, pancreas, adipose tissue and 
placenta [38].  They are closely associated with endothelia cells and appear to 
function similarly to MSCs [39].  They have a similar cell phenotype and 
immunophenotype (CD146+, CD34-, CD45- and CD56-) to MSCs and are capable of 
osteogenesis, adipogenesis and chondrogenesis in vitro [38, 40-42].  Distinct 
similarities have been shown between in situ and in vitro properties of MSCs and 
pericytes [43]. 
The perivascular niche is unlikely to be the only MSC niche [38].  Avascular 
tissues like cartilage also contain MSCs [44].  Hematopoietic stromal cells (HSCs) are 
believed to have at least two niches, the endosteal niche on the surface of trabeculae; 
and the perivascular niche within bone marrow sinusoids [45].  Ways to identify and 




1.3 Therapeutic Effects of Multipotent Stromal Cells 
1.3.1 Trophic Effects of Multipotent Stromal Cells 
Tissue MSCs are thought to replace cells lost to age, disease or trauma.  They are also 
known to have a paracrine effect, production of local bioactive factors.  The MSC 
production of cytokines and growth factors is reported to be relatively constant among 
different donors and not influenced by age or health status [46].  However, the 
bioactive factors produced by MSCs are affected by differentiation and the local 
environment [46].  Effects of these factors can be direct, inducing intracellular 
signaling, indirect, stimulating other cells in the vicinity to secret other bioactive 
factors, or both.  The indirect activity is referred as trophic, since the MSCs do not 
differentiate themselves, but their bioactive factor secretion mediates cell behavior.  
Some trophic effects include local immune suppression, enhancing angiogenesis, 
inhibiting apoptosis and fibrosis and inducing differentiation and mitosis of tissue-
specific and tissue-intrinsic progenitors [46].   
Exogenous MSCs have been shown to contribute to tissue repair by homing to 
damaged tissue where they secrete paracrine and autocrine signals to influence local 
cellular dynamics.  This effect has been shown in spinal cord injury, myocardial 
infarction, meniscus, cartilage and bone repair and Crohn’s disease [28, 47-49].  
Chopp et al showed that rat marrow MSCs promote intrinsic neural progenitor cells to 
regenerate functional neurological pathways in damaged brain tissue when applied 
directly or systemically.  Notably, the exogenous cells do not differentiate into 
neurons or neuronal support cells to mediate the effect [47, 50].   
1.3.2 Immunomodulatory Effects of Multipotent Stromal Cells 
The MSCs play multiple roles in immunomodulation.  The 




transplantation [51].  By definition, major histocompatibility complex (MHC) class I 
proteins are expressed by MSCs while MHC class II proteins are not [52, 53].  
However, this characteristic is influenced by the microenvironment.  The MHC II 
expression can be either upregulated or downregulated by IFN-γ [54-57].  Therefore, 
the immunosuppressive effect of MSCs is independent of MHC-I and II expression. 
The MSCs modulate the functions of the major immune cells including T, B cells, 
natural killer (NK) cells, monocytes and dendritic cells (DC).  They suppress T-cell 
proliferation, cytotoxic T lymphocyte formation and IFN-γ production, thus inducing 
the expansion of Treg cells [58-61].  MSCs also inhibit B cell proliferation, 
differentiation, chemotactic functions and IgG secretion [62-64].  Additionally, they 
inhibit NK cell proliferation, NK cell-mediated cytolysis and NK cell production of 
IFN-γ [65].  They also inhibit both DC maturation and activation, and differentiation 
of monocytes to DCs, thus increasing T cell anergy [66].  Thus, MSCs are currently 
being used to reduce immunological rejection [51]. 
The MSC immunosuppressive function is mediated by soluble factors, since 
cellular communication is not contact-dependent [51, 67].  Several factors have been 
found in co-culture systems of immune cells and MSCs (human and murine BMSCs, 
placenta and dental pulp MSCs), such as stem cell factor, interleukin (IL)-1β, IL-6, 
IL-8, IL-10, IL-12, IFN-γ, transforming growth factor-β1, vascular endothelial growth 
factor (VEGF), prostaglandin E2, macrophage colony-stimulating factor, hepatocyte 
growth factor and indoleamine 2,3-dioxygenase [65, 68-71].  However, mechanisms 
of how MSCs interact with immune cells are still unclear.  Research of this issue is 




1.3.3 Multipotent Stromal Cell Homing 
MSCs have been found localized in inflamed tissue.  Up to 100 times more MSCs are 
found in the synovial fluid  patients with ligament injury compared to healthy donors 
[72].  Additionally, compared to non-injured mice, an increased amount of circulating 
BMSCs are observed in peripheral blood from mice with intimal hyperplasia [73].  
The arrest of MSCs within the vascular system of a tissue followed by transmigration 
across the endothelium is called homing [74].  It is a prerequisite for MSCs to 
function, particularly when MSCs are administered by systemic infusion.  Homing 
requires a multistep process with adhesive and signaling events, including adhesion to 
the endothelium, transendothelial migration, chemotaxis, matrix degradation and 
invasion and in situ differentiation [74, 75].  The mechanisms of MSC homing are not 
fully understood, but preliminary studies show that MSCs share at least some features 
with homing of leukocytes to sites of inflammation [76].  Initially, cells are rolled on 
the endothelium by selectins, which are expressed in inflamed venules [77].  This 
process allows cytokines to activate MSCs and stimulates the cells toexpress high 
affinity integrins to help them adhere to the vascular endothelium of the target site 
[78].  Then, cells migrate transendothelially and invade into ECM by integrin-ECM 
molecules interactions and matrix degradation [79, 80]. 
Numerous chemokines are reportedly involved in the recruitment of MSCs to 
the target tissue.  For example, the upregulation of stromal cell derived factor-1 
enhances murine BMSC and endothelial progenitor cell homing and incorporation 
into ischemic tissues [76, 80].  Interleukin 8 and its cellular receptors also contribute 
to homing of intravenous infused human CD34+ progenitor cells to ischemic 
myocardium in rats [81].  Vascular endothelial growth factor induces bone marrow-




integrin α4β1, E- and P-selectin are also involved in recruiting BMSCs, endothelial 
progenitor cells in target tissues like tumor, hind limb ischemia and myocardial 
infraction [83-88].  These factors may be further used to attract MSCs to specific 
locations in further studies. 
Culture conditions have a significant impact on MSC homing.  Freshly 
isolated mouse MSCs have higher homing capacity compared to culture-expanded 
populations [89].  Homing receptors like CXC chemokine receptor type 4 are 
expressed in stromal vascular fraction cells but not in cultured MSCs [28].  
Transendothelial MSC migration is reduced with in vitro passage, potentially due to 
production of tissue inhibitor of metalloproteinases-3, a natural MMP inhibitor [90].  
Another reason may be loss of surface markers during in vitro culture.  Interestingly, 
simulation of ischemic environments in vitro or hypoxic preconditioning, seems to 
enhance MSC transendothelial migration by upregulation of MSC MMP production 
[91, 92].  All of these factors need to be considered to enhance MSC therapy. 
1.3.4 Multipotent Stromal Cell Heterogeneity 
Differences in MSCs among donors may contribute to differences in clinical trial 
outcomes [93].  Different patient donors have different MSC in vitro expansion rates 
and differentiation potentials [94].  Results are also influenced by factors such as 
donor age and health status, harvest technique, culture methods and plating density.  
Plastic adherence selects for a heterogenous MSC population.  MSC heterogeneity 
seems to be reduced by consistency among isolation and culture procedures and 
selection of MSCs based on surface marker expression.  There is no single marker 
unique to MSCs with which to yield a pure population.  So, panels of markers like 
CD29, CD44, CD71, CD73, CD90, CD105, CD106, CD120a, CD124, CD146, 




[95].  Additionally, genomic transcripts and proteins have been used to identify MSC 
amongst hematopoietic, endothelial and periosteal cells and synovial fibroblasts [96].   
Use of such techniques does not confirm multipotentiality of an MSC isolate.  
A significant percentage of MSCs that were capable of osteogenesis in vitro did not 
form heterotopic osseous tissue in vivo [97].  Additionally, MSCs lose their 
multipotentiality and change immunophenotype with increasing passage.  
Subpopulations of MSCs isolated with different sets of surface markers have different 
properties.  For example, human BMSCs that are CD271+, W8B2+ and CD56+ have 
higher chondrogenic than adipogenic potential [98].  A cellular subset of CD105+low 
human ASCs was found to be more osteogenic than CD105+high ASCs both in vitro 
and in vivo [99].  These results confirm the importance of identifying characteristics 
of different MSC immunophenotypes.   
 Heterogeneity also exists among MSCs from different tissue sources.  Rat 
MSCs derived from epididymal adipose had higher multipotentiality than epicardial 
cells in vitro, but their expansion rates were lower [100].  Joint tissue-derived MSCs, 
including ASCs and SSCs, displayed significantly higher chondrogenic capacity than 
BMSCs in vivo [101].  Additionally, despite similar in vitro capacities, human ASCs 
exhibited significantly higher potential to differentiate into muscle cells than 
umbilical cord MSCs in vivo [102].  Compared to subcutaneous fat, patellar adipose 
from human patients with knee osteoarthritis (OA) have a lower number of capillary-
like structures and higher numbers of stromal and alkaline phosphatase CFUs [103].   
Questions remain about how disease affects MSCs.  It is not known if 
inflammation in the local environment affects MSCs or if they are protected within 
their niche.  The BMSCs from iliac crest or tibia/femur in OA patients had 




capacities than those from patients without OA, but the osteogenic potential was not 
affected [104].  In contrast, MSCs isolated from mice with vascular injuries retained 
in vitro trilineage differentiation potential up to 10 passages while those from normal 
mice MSCs retained the trilineage differentiation property only to passage 1 [73].  
There are many possible reasons for variable results from MSCs harvested from 
normal versus diseased or injured tissues including type and level of disease, harvest 
location, cell types, individual variation, species differences and MSC isolation and 
expansion methods.  Therefore, in order to identify factors that contribute to different 
MSC behavior, variables should be limited as much as possible. 
1.3.4 Adipose Derived Multipotent Stromal Cells (ASCs) versus Preadipocytes 
ASCs are important to innate immunity and angiogenesis, two properties that are vital 
to development of viable tissues derived from them.  It is proposed that there are two 
types of precursor cells in adipose tissue, preadipocytes with limited differentiation 
capacities and ASCs [105].  Compared to ASCs, preadipocytes have a shorter lifespan 
and cannot be maintained in vitro for prolonged periods of time [105].  Additionally, 
preadipocytes are reported to be CD34+ in contrast to ASCs, the majority of which 
are CD34- [18, 19].  Preadipocytes secrete numerous inflammatory cytokines such as 
TNF-α and are sensitive to lipopolysaccharide activation [106].  They also have many 
proteins in common with monocyte/ macrophages, such as adipocyte protein 2, 
peroxisome proliferator-activated receptors-gamma (PPAR-γ), and nicotinamide 
adenine dinucleotide phosphate-oxidase [107, 108].  Preadipocytes can also display 
phagocytic activity [109, 110].  Macrophage-like properties decline after commitment 
of preadipocytes into adipocytes, so they may be limited to adipocyte progenitors 




 Preadipocytes are also have properties of endothelial-like progenitors [111].  
Development of a capillary network is required to support optimal tissue function and 
remodeling.  Human CD34+/CD31- ASCs have been shown to differentiate into an 
endothelial phenotype in vitro and in vivo [53].  Additionally, adipogenic lineage 
proteins induce potent proangiogenic factors, including monobutyrin, VEGF and 
leptin [112-115].  Thus, ASCs may be beneficial in vascular reconstruction during 
tissue regeneration. 
1.4 Multipotent Stromal Cells in Tissue Engineering 
MSCs in combination with scaffolds are often used for tissue engineering.  Cell-
scaffold constructs have the potential to provide a spatial and temporal 
microenvironment that mimics the stromal cell niche to support cell proliferation, 
regulate cell function and promote tissue regeneration [116].   
1.4.1 Cell Sources 
Potential MSC sources include fully differentiated, adult cells, adult MSCs, 
embryonic stem cells (ESCs) and induced-pluripotent stem cells [117].  Fully 
differentiated adult cells have limited proliferation capacity and lifespan both in vitro 
and in vivo [118].  Compared to MSCs, ESCs have higher differentiation potential.  
However, their application is limited due to ethical issues, potential risk of tumor 
formation and immune rejection.  Therefore, adult MSCs have become a popular 
source in tissue engineering.  There are over 20 tissue sources of adult MSCs.  
Historically, the tissue forming capacity of MSCs was thought to be limited to the 
mesoderm.  However, recent evidence shows that MSCs have greater plasticity (the 
capacity to differentiate into cell types from different germ layers) than previously 
thought [13].  In fact, under appropriate culture conditions, MSCs are capable of 




transdifferentiation or plasticity is not fully understood, this MSC characteristic has 
distinct advantages for tissue engineering.   
 Cell sources can also be categorized as autologous, allogeneic and xenogeneic 
cells.  Autologous cells are least likely to undergo immune rejection, since they are 
from the same individual body.  However, they are not always available, and may not 
be viable or expandable in vitro.  Harvest of autologous cells may cause donor site 
morbidity [121].  In addition, cells may be influenced by diseased conditions.  
Allogeneic cells from individuals of the same species and xenogeneic cells from 
individuals of different species offer alternatives to this situation [122].  Concerns 
surrounding allo- and xenogeneic sources also include disease transmission, infection 
and immune rejection [123, 124]. 
1.4.2 Scaffold Carriers 
Extra-cellular matrix varies among tissues [125].  The ECM has five major functions 
[126].  It provides structural support and a physical environment so that cells are able 
to attach, proliferate, migrate, differentiate and function.  It also confers mechanical 
properties to the tissue.  The ECM provides bioactive cues for regulating the activities 
of residing cells.  Finally, the ECM provides a dynamic environment for 
vascularization and new tissue formation.  The goal of scaffold synthesis is to 
replicate the ECM of the target tissue to give the best chance to recreate it.  Scaffolds 
should be composed of materials to give it similar physical and mechanical properties 
as the native tissue as well as degradation that occurs at the same rate as tissue 
generation.  Porosity should be sufficient for nutrient transfer and cell adhesion 
without compromising mechanical strength.  
 Four wide categories of scaffolds designed to carry MSCs include porous 




hydrogel [126].  Porous structures composed of natural or synthetic biodegradable 
and biocompatible materials are one of the most popular approaches to scaffold 
carriers.  Scaffolds can be designed to mimic hard and soft tissue ECM.  The ideal 
pore diameter is around 150 µm for hard tissue formation and 200 – 250 µm for soft 
tissue formation [124].  Natural ECM that is decellularized has similar composition 
and mechanical properties as native tissue ECM.  However, complete 
decellularization is required to minimize immunogenicity, and tissue properties may 
be altered by harvest, decellularization and deproteinization [127, 128].  Layers of 
sheets of confluent cells within the ECM they produce are typically used to 
reconstruct highly cellular tissues like epithelium and endothelium.  Injectable 
hydrogel has been applied for cartilage and soft tissue generation with MSCs [129, 
130].  Hydrogel formulations can be made with both natural and synthetic materials 
by physical and chemical crosslinking [131, 132].  Scaffolds are customized to the 
intended in vivo application.  Tissue-specific properties and the amount of tissue to be 
regenerated are considerations when identifying scaffold carriers.  
There are general approaches to prepare MSC-scaffold constructs for 
implantation.  One is to inject MSCs into scaffolds during surgery [133]. Another 
approach is to culture MSC-scaffold constructs in differentiation medium for a period 
of time (7-21 days) to induce cell differentiation and tissue specific ECM production 
and then implant them orthotopically [134].  Pre-seeding of human BMSCs on the 
poly-L lactic acid (PLLA) mesh has higher osteogenic potential in rats compared to 
injecting MSCs into the scaffold during surgery [135].  Another approach is to 
encapsulate MSC-scaffold constructs within protective coatings and allow cells to 
mature in vitro in an orthotopic implantation site.  Oligo(poly(ethylene glycol) 




chondrocyte potential in vitro [136].  Co-encapsulation of TGF-β3 in hyaluronic acid 
hydrogels with human BMSCs supports neo-cartilage formation when implanted 
subcutaneously in mice [137].  So far, there is no clear agreement about which 
approach is better.  Specific circumstances should be considered to identify MSC-
scaffold pre-implantation conditions, including material types of the scaffold, cell 
types and types of tissue forming.   
1.4.3 Bioreactors for 3-Dimensional Culture 
Monolayer culture does not mimic the mechanics and cell-cell or cell-ECM 
orientation.  Problems associated with 3-D scaffolds include difficulties with gas 
exchange and nutrient delivery.  Additionally, cell seeding is more difficult in 3-D 
scaffolds, and non-homogenous cell distribution can result in non-uniform tissue 
formation.  A 3-D cell culture system is a natural step between 2D in vitro culture and 
in vivo conditions.   
Bioreactors are dynamic systems used to load and culture cells on scaffolds 
[138].  There are a number of different types of bioreactors including rotating wall 
vessels, direct perfusion systems and spinner flasks [138].  Spinner flasks and rotating 
wall vessels are normally used to enhance nutrient transport into the porous structure 
by rotating the medium [139].  A perfusion system is a more complex setup designed 
to direct fluid through the inside of the construct [140].   
 Perfusion bioreactors provide a more uniform distribution of the medium 
within scaffolds compared to spinner flask and rotating vessels, and they provide 
mechanical stimulation of cells in the scaffold in the form of shear stress [141].  Shear 
stress is critical for cell differentiation and ECM deposition [142].  Perfusion 
bioreactors are preferred for orthopedic tissue engineering [143].  The chamber 




should approximate the sides of the scaffold.  Fluid is moved through the chamber by 
a pump.  Common flow rates range from 0.3 – 3.0 ml/min [144].  Perfusion 
bioreactors have been shown to increase production of growth factors that contribute 
to cell differentiation [145].  Dynamic perfusion culture also helps reduce the 
concentration of these factors in the local area and promote differentiation of rat 
BMSCs throughout starch-based fiber scaffolds [145].  Production and distribution of 
growth factors in vitro may be a benefit of perfusion bioreactors for tissue 
regeneration in vivo.  However, perfusion bioreactors require optimization for 
targeted tissue production.  Cell seeding is crucial for tissue regeneration and is 
specific to tissue type.  It also ranges widely for a given purpose.  For example, 
human anterior cruciate ligament regeneration in a bioreactor with BMSCs has been 
reported to require between 106 to 108 cells/cm3 [123, 146].  An optimal cell density 
should be based on both cell (expansion and differentiation) and tissue (type, density, 
matrix deposition) characteristics.  Flow rate is another parameter that varies widely 
among different scaffold types, cell sources, tissues, and system capacities [123].  
Most importantly, more in vivo models should be tested before putting the perfusion 
bioreactors into a clinical setting. 
1.5 Veterinary MSC Applications 
In general, MSC-applications are at very early stage in veterinary medicine.  The 
mechanism of MSC function in vivo is still not fully understood, and efficacy in vitro 
or in preclinical animal studies has not been established.  Perhaps the earliest 
application of MSCs in veterinary medicine has been the use of MSCs to treat equine 
suspensory ligament desmitis using 20 ~ 60 ml of bone marrow mononuclear cells 
[147].  Treatment led to an improvement in athletic function rates compared to 




therapeutic effects were from MSCs, since only 1 in 10,000 - 15,000 cells of 
mononuclear cells of bone marraow aspirate are estimated to be MSCs [148].  MSC-
mediated therapies have been also been applied to dogs to treat tendon, ligament and 
cartilage/joint injuries.  So far, different cell sources have been used, including the 
adipose-derived stromal vascular fraction (SVF) and culture-expanded BMSCs and 
ASCs.  Compared to culture-expanded cells, SVF require a larger tissue harvest 
volume to achieve therapeutic doses.  Also, culture-expanded MSCs need to be fully 
characterized according to the minimum criteria mentioned above.  BMSCs are the 
most investigated MSCs in veterinary medicine, and have been characterized in 
horses, dogs, and cats, among other domestic species.  They have displayed 
comparable expansion rates, differentiation potential and surface marker expression 
as human and rat BMSCs.  Adipose tissue is another option for MSC harvest with a 
500 fold greater number of SVFs [149].  With a treatment of 4.2 ~ 5 x 106 SVF from 
adipose, the lameness, pain and range of motion have been significantly improved for 
dogs with chronic OA [150].  Both culture-expanded BMSCs and ASCs have been 
applied in cats with chronic kidney disease (CKD).  In a pilot study, two out of the 
four cats administered 1 ~ 4 x 106 ASCs by unilateral intrarenal injection had a 
modest increase in glomerular filtration rate along with a mild decrease in serum 
creatinine concentration, indicating improved kidney function [151].  This and other 
studies emphasize the need for controlled in vitro and in vivo studies as well as 
clinical trials.   
 This dissertation focuses on the clinical translation of MSC-based therapies.  
Chapter two is to identify the optimal MSC intra-articular source for general 
orthopedic therapies.  Applications include direct administration into the joint to treat 




ligaments and tendons.  Chapter three discusses a new isolation method of MSCs 
from excised feline tissue.  The purpose of this study is to collect MSCs without the 
need for additional tissue harvest.  Compared to canine and equine, MSCs in feline 
remain largely unexplored.  This study also provides vital information on in vitro 
culture, multipotentiality and cryopreservation.  As a continuation of chapter two, 
chapter four surrounds generation of viable canine cranial cruciate ligament (CrCL) 
structures using ASCs and biocompatible scaffolds under custom induction and 
perfusion culture conditions.  Results of these studies are intended to contribute tto 



















CHAPTER 2. CANINE INTRA-ARTICULAR MULTIPOTENT STROMAL 
CELLS (MSC) FROM ADIPOSE HAVE THE HIGHEST IN VITRO 
EXPANSION RATES, MULTIPOTENTIALITY, AND MSC 
IMMUNOPHENOTYPES  
2.1 Introduction 
Rupture of the cranial cruciate ligament (CrCL) is the leading orthopedic disorder of 
the canine stifle [152, 153].  Concomitant intra- and periarticular damage occurs with 
70% of CrCL ruptures, and quality of life is reduced by the progressive pain, 
dysfunction, and osteoarthritis [154, 155].  Many tissues within the stifle have limited 
regenerative and reparative capacities, so surgical intervention is often necessary to 
restore joint function [156].  Current surgical options do not necessarily restore 
damaged tissues or inhibit joint degeneration [157].  The emerging field of tissue 
engineering with adult multipotent stromal cells (MSCs) has significant potential for 
generation of viable, functional, engineered stifle tissues to replace those lost to injury 
and degeneration [158].  Meanwhile, knee pain is a complaint in as many as 20% of 
the general adult population in United States, and more than 20 million people seek 
medical attention for knee pain each year [159].  The canine stifle (knee) is an 
established large animal model for human knee studies given its similar anatomy 
structure and joint kinetics [160]. The model is routinely used to develop and test 
surgical procedures, implants, and mechanisms of CrCL treatment and reconstruction 
[161, 162].  Additionally, significant preclinical work surrounding isolation, 
characterization and therapeutic application of adult MSCs has been done with the 
model [163-165].    
Ideal cell candidates for intra-articular tissue regeneration should have high 
proliferative capacity, produce tissue specific extracellular matrix and survive in the 
intra-articular environment [166].  Orthotopic adult stromal cells have greater 




Intra-articular stromal cells have better expansion capacity and potential for stifle 
joint tissue regeneration than cells from other sources [168].  Infrapatellar (IFP) 
adipose and synovium are established intra-articular MSC sources, and CrCL cell 
isolates are reported to have higher expression of ligament specific phenotypic 
markers than peri-articular ligaments and tendons [169, 170].  For the potential 
benefits of orthotopic stromal cell tissue regeneration to be realized in clinical stifle 
therapies, it is critical to identify the optimum intra-articular source of adult MSCs.  A 
direct comparison of cell isolate phenotypes and their in vitro expansion capacities 
and multipotentiality within individuals is key to achieving this goal.     
Recently, canine IFP adipose derived multipotent stromal cells (ASCs) were 
shown to have greater or equal expansion capacity to bone marrow MSCs and 
comparable multipotentiality following cryopreservation [171].  Based on this 
information and the stated goal above, we hypothesized that stifle joint MSCs from 
IFP (ASC) had higher stromal cell tissue density, in vitro expansion rates, 
multipotentiality, and MSC cell immunophenotypes than synovium lining the joint 
capsule (SSC) and synovium surrounding the CrCL (LSC) up to cell passage (P) 6. 
2.2 Materials and Methods 
2.2.1 Ethics Statement 
All animal experiments were approved by the LSU Institutional Animal Care and Use 
Committee.   
2.2.2 Study Design 
Synovium lining the joint capsule, IFP, and CrCL were collected from one normal 
stifle of six mixed breed female dogs (23.1 ± 0.9 kg, 3.3 ± 0.4 years, mean ± SEM) 




in the study had no detectable radiographic changes or visible intra-articular 
abnormalities.  The following assessments were performed on cells from all tissues in 
each dog: P0-6 cell doublings (CD) and doubling times (DT); P0, 3 and 6 CD29+, 
CD44+, CD90+, CD34+, and CD45+ cell percentages; P0, 3 and 6 fibroblastic, 
osteogenic, and adipogenic colony forming unit frequencies; P0 chondrogenic pellet 
alcian blue (proteoglycan) staining; P0 and 3 stromal (undifferentiated) and 
differentiated (adipogenic, osteogenic, and chondrogenic) cell MSC and lineage 
specific target gene mRNA levels.  Cell immunophenotypes were also determined in 
the stromal vascular fraction (SVF) of pooled tissue harvests collected immediately 
post-mortem from both normal stifles of ten adult, female, mixed-breed dogs 
euthanized for unrelated reasons.  Pooling was necessary for adequate cell numbers, 
so only one SVF sample for each cell type was evaluated for nucleated cell density 
and with flow cytometry. 
2.2.3 Cell Isolation and Expansion 
Adipose tissue and joint capsular synovial cells were isolated sterilely according to a 
published protocol with minor modifications [171].  Briefly, adipose tissue and 
synovium were minced into small pieces, and the CrCL surface was vigorously 
lavaged with PBS to detach the synovial membrane.  Tissues were then digested with 
collagenase solution (DMEM-Ham’s F12 [HyClone, Logan, UT], 0.1% type I 
collagenase [Worthington, Biochemical Corporation, NJ], 1% bovine serum albumin).  
After 1 hr, the pellet resulting from centrifugation (260 g, 5 min) was resuspended in 
stromal medium (DMEM-Ham’s F12, 10% fetal bovine serum [FBS] [HyClone], 1% 
antibiotic/antimycotic solution) and filtered (100 µm, BD Falcon, Bedford, MA) 
following addition of an equal volume of red cell lysis buffer (0.16 mol/L NH4Cl, 




(CellStar, Greiner, NC) at a density of 5 x 103 cells/cm2 in stromal medium and 
cultured under standard conditions (37°C, 5% CO2).  Medium was refreshed after 4 
hours and then every 2-3 days.  Subsequent passages were performed at 80% 
confluence with a cell seeding density of 5 x 103 cells/cm2.  For purposes of this study, 
primary cell isolates were considered the SVF.  The first cell passage of the primary 
cells was P0.   
2.2.4 Cell Expansion (P0-6)  
Cell doublings (CD) and cell doubling time (DT) were determined with duplicate 
cultures in 12-well plates at an initial seeding density of 5 x 103 cells/cm2 [172].  Cells 
were counted after 2, 4, and 6 days of culture.  CD and DT were calculated with the 
formulae: CD= ln(Nf /Ni)/ln(2) DT= CT/CD (Ni: initial cell number; Nf: final cell 
number; CT=culture time) [173].  
2.2.5 Multipotentiality (P0, 3, 6) 
Limiting-dilution assays to determine fibroblastic (CFU-F), adipogenic (CFU-Ad), 
and osteogenic (CFU-Ob) colony forming unit frequencies [174].  A total of 5 x 103, 
2.5 x 103, 1.25 x 103, 6.25 x 102, 3.12 x 102, or 1.56 x 102 cells were placed in each 
well of one row (one concentration/row, 8 replicates/concentration) in a 96-well plate.  
Cells were cultured in stromal medium for 7 days.  Fibroblastic (CFU-F) colonies 
were then fixed with 1% paraformaldehyde and stained with 0.1% toluidine blue.  For 
adipogenesis (CFU-Ad), cells were cultured in stromal medium for 7 days, followed 
by culture in adipogenic medium (DMEM-Ham’s F12, 3% FBS, 1% 
antibiotic/antimycotic solution, 33 µmol/L biotin, 17 µmol/L pantothenate, 1 µmol/L 
dexamethasone, 100 µmol/L indomethacin, 1 µmol/L insulin, 0.5 mmol/L 
isobutylmethylxanthanine [IBMX], and 5 µmol/L rosiglitazone) for 21 days.  Wells 




were cultured in stromal medium for 7 days and then cultured in osteogenic medium 
(DMEM-Ham’s F12, 10% FBS, 1% antibiotic/antimycotic solution, 10 mmol/L β-
glycerophosphate, 10 nmol/L dexamethasone, and 50µg/ml sodium 2-phosphate 
ascorbate) for 21 days.  Colonies were fixed in 70% ETOH and stained with 2% 
alizarin red.  Wells were considered positive for MSC, adipogenesis, or osteogenesis 
when there were ≥10 toluidine blue-stained colonies, ≥10 oil red O-stained colonies, 
or ≥1 alizarin red-stained colonies, respectively [175].  The ratio of negative to total 
wells in rows (one for each concentration) containing negative wells were used to 
estimate the CFU for each concentration using the equation F=e-x (F: ratio of negative 
to total wells within a row (concentration), e: natural logarithm constant 2.71, x: CFU 
number per well).  Based on a Poisson distribution of a clonal cell lineage, the value 
of F = 0.37 occurs when the number of total cells plated in a well contains a single 
CFU.13,14  The mean value from each plate was used as the CFU for each animal/cell 
type/differentiation medium.  For chondrogenesis, 2.5 x 105 cells were centrifuged 
(200 x g, 5 min) to form a pellet in a 1.5 ml microcentrifuge tube following 7 days of 
culture in stromal medium.  The pellet was cultured in chondrogenic differentiation 
medium (DMEM-Ham’s F12, 3% FBS, 1% antibiotic/antimycotic solution, 50 µg/mL 
abscorbate phosphate, 100 nmol/L dexamethasone, 40 µg/mL proline, 2 mmol/L 
sodium pyruvate, 1% ITS, and 10 ng/mL TGF- β3) for 21 days with media changes 
every 2–3 days.  Pellets were formalin-fixed, paraffin-embedded, sectioned (5 µm) 
and stained with alcian blue. 
2.2.6 Expression of marker genes 
Total RNA was isolated from cells (RNAqueous Kit, Ambion, Grand Island, NY), 
DNase-treated, and reverse-transcribed using oligo (dT) primers and Moloney murine 




extracted by homogenization in TRI Reagent (Sigma Aldrich, St Louis, MO).  Target 
gene mRNA levels were quantified with qRT-PCR using SYBR Green technology 
(MJ Research Chromo4 Detector, Bio-Rad Laboratories).  Canine-specific primers for 
MSC and adipogenic, osteogenic, and chondrogenic lineages were used (Table 1) 
[174].  Values were normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH).  Relative gene expression was quantified according to 2-ΔΔCt [176]. 
Table 1 Canine-specific primer sequences for adipogenic, osteogenic, chondrogenic, 
and progenitor genes 













































PPAR-γ, peroxisome proliferator-activated receptor gamma; Col1, collagen type I; 
OPG, osteoprotegerin; Col2, collagen type II; Sox2, sex determining region Y-box 2; 
Nanog, homeobox protein nanog. 
2.2.7 Immunophenotype  
Cell aliquots (105) were resuspended in 200 ml PBS containing 5 ul antibody.  Cells 
were incubated with antibodies specific for canine antigens or validated for canine 
cross reactivity against PE-CD34, FITC-CD44, PE-CD45, and PE-CD90 for 30 min at 




paraformaldehyde.  For non-conjugated CD29 staining, the cells were incubated with 
antibody for 30 min at room temperature.  They were then incubated with a secondary 
antibody, FITC-conjugated goat anti-mouse IgG (Sigma Aldrich) for 30 min, washed 
with PBS, and fixed as above.  For negative autofluorescence control, cells were not 
incubated with antibodies.  Cellular fluorescence was evaluated by flow cytometry 
using a FACSCalibur flow cytometer and CellQuest Pro software (BD Biosciences, 
San Jose, CA).  Cell percentages expressing each antigen were determined.  Due to 
low SVF cell numbers, flow cytometry was performed on representative samples for 
each tissue type using pooled cells from unrelated dogs.  Pooling was necessary for 
adequate cell numbers so only one sample was processed for each antibody. 
Table 2 Antibodies against canine MSC surface markers 





CD29 N/A β1 integrin BD Biosciences 610468 Human 
CD34 PE Hematopoietic progenitor  (HSC) 
BD 
Biosciences 559369 Canine 
CD44 FITC Hyaluronic acid receptor eBiosciences 115440 Canine 
CD45 PE HSC, leukocyte antigen eBiosciences 125451 Canine 
CD90 PE Thy-1, fibroblasts, MSC, HSC eBiosciences 125900 Canine 
IgG FITC Secondary antibody Sigma-Aldrich F9006 Mouse 
2.2.8 Statistical Analysis  
All results are presented as mean ± SEM.  ANOVA models (GraphPad Prism, La 
Jolla, CA) were used to compare CD, DT, CFU frequency, RNA levels, and cell 
surface marker percentages among passages within cell types and among cell types 
within passages.  Tukey’s post hoc tests were applied for multiple group comparisons 






2.3.1 Cell Harvest   
Using pooled samples, 3.4 x 105 nucleated cells/g were isolated from IFP (2 – 
3g/stifle), 3.0 x 105 cells/g from synovial membrane (1 – 2g/stifle), and 1.1 x 106 
cells/g of CrCL (2.2 x 105 cells/CrCL). 
2.3.2 Cell Expansion 
Day 2 and day 4 cell counts were used as the initial number to calculate expansion 
rates on days 4 and 6, respectively.  Differences were not significant between days, so 
data was collapsed over this variable.  The overall (P0-P6 combined) CD for ASC, 
SSC, and LSC were 1.7 ± 0.1, 1.5 ± 0.1, and 1.2 ± 0.1 CD/day, respectively (Table 3).   
Table 3 Canine ASC, SSC, and LSC cell doublings (CD/day) for P0-6 (mean ± SEM) 
 P0 P1 P2 P3 P4 P5 P6 
ASC 1.9±0.2 A,a/b 2.0±0.2 A,a/b 2.1±0.2 A,a 1.6±0.2 A,a/b/c 1.8±0.2 A,a/b 1.4±0.6 A,b/c 0.9±0.1 A,d 
SSC 1.9±0.2 A,a 1.8±0.2 A,a 1.7±0.2 A,a 1.7±0.2 A,a 1.5±0.2 A,a 1.3±0.1 A,a 0.5±0.1 B,b 
LSC 1.5±0.1 A,a/b 1.8±0.1 A,a 1.5±0.2 A,a/b 1.4±0.2 A,a/b 1.1±0.1 B,b/c 0.8±0.1 B,c/d 0.4±0.1 B,d 
Columns with different upper-case letters within passages and those with different 
lower-case letters within cell types are significantly different from each other 
(P<0.05).  
 
The corresponding overall DT (P0-6) were 0.7 ± 0.1, 0.7 ± 0.1, and 0.8 ± 0.1 days/CD 
(Table 4).  Within cell types, P6 ASC had significantly lower CD than P0, 1, 2, and 4, 
and significantly higher DT than P0-4. The P6 SSC had significantly lower CD and 
higher DT than all previous passages, and P6 LSC had significantly lower CD and 
higher DT than P0-4.  There were no significant differences in CD among cell types 
for P0-3.  For P4-6, LSC CD was significantly lower than ASC.  The P5 SSC CD 
value was significantly higher than LSC.  After P5, SSC and LSC had significantly 




Table 4 Canine ASC, SSC, and LSC doubling times (days/CD) for P0-6 (mean ± 
SEM) 
 P0 P1 P2 P3 P4 P5 P6 
ASC 0.6±0.1A,a 0.6±0.1A,a 0.5±0.0A,a 0.8±0.1 A,a 0.6±0.1 A,a 0.8±0.1 A,a/b 1.2±0.1 A,c 
SSC 0.6±0.1 A,a 0.7±0.1 A,a 0.7±0.1 A,a 0.7±0.1 A,a 0.8±0.1 A,a 0.9±0.9 A,a 3.0±0.6 B,b 
LSC 0.7±0.1 A,a 0.6±0.1 A,a 0.8±0.1 A,a 0.8±0.1 A,a 1.0±0.1 A,a 1.6±0.2 B,b 3.7±0.6 A,c 
Columns with different upper-case letters within passages and those with different 
lower-case letters within cell types are significantly different from each other 
(P<0.05).  
2.3.3 Multipotentiality 
All cell types displayed characteristic adipogenic (See A-C in Figure 1), osteogenic 
(See D-F in Figure 1), and chondrogenic (See G-H in Figure 1) differentiation.  The 
CFU frequency indicates the minimum number of cells that includes one capable of 
forming a fibroblastic (CFU-F) colony or differentiating into osteogenic (CFU-Ob) or 
adipogenic (CFU-Ad) cell lineages.  Results were presented as frequencies, so higher 
numbers indicate more cells required for a cell with the indicated reduced 
differentiation capacity.  Due to limited cell expansion past P4, P6 LSC were not 
included in CFU assays.  Within cell types, the P6 ASC and SSC CFU-F were 
significantly higher than P0, and the LSC P3 CFU-Ad was significantly higher than 
P0 (Table 5).  Among cell types, P0 and P3 LSC had significantly higher CFU-F, 
CFU-Ad and CFU-Ob than ASC.  The P3 SSC had significantly higher CFU-Ad than 







Figure 1 Trilineage differentiation of canine ASCs, SSCs and LSCs 
P0 ASC, SSC, and LSC after 21 days culture in adipogenic (A, B and C), osteogenic 
(D, E and F), and chondrogenic medium (G, H, and I).  Lipid droplets stain red with 
Oil Red O, calcified colonies stain red with Alizarin red, and proteoglycans stain blue 
with Alcian blue.  A stromal cell pellet cultured in stromal medium and stained with 
Alcian blue (J) is included for comparison.  Original magnification: A-F, 10x, G-J, 
63x, scale bar = 600 µm. 
 
Table 5 Colony forming unit frequencies for canine ASC, SSC, and LSC following 
fibroblastic (CFU-F), adipogenic (CFU-Ad), or osteogenic (CFU-Ob) induction  
  ASC SSC LSC 
CFU-F 
P0 212.0±45.6A,a 248.3±42.7 A,a 1343.5±170.6 B,a 
P3 565.6±104.9A,a 919.7±158.9 A,b 4423.4±871.5 B,b 
P6 3888.2±747.2 A,b 7834.7±1892.4  B,c  
CFU-Ad 
P0 155.0±58.6 A,a 739.1±157.7 B,a 1570.4±213.6 C,a 
P3 387.5±88.8 A,a 1528/7±269.1 B,b 4411.4±357.2 C,b 
P6 6602.8±979.8 A,b 9350.0±65.7 B,c  
CFU-Ob 
P0 703.6±193.2 A,a 820.6±106.4 A,a 1734.1±196.4 B,a 
P3 1274.8±302.5 A,a 1596.6±235.6 A,b 3670.8±494.2 B,b 
P6 6266.7±945.4A,b 10050.0±1068.9B,c  
Columns with different upper-case letters within passages and those with different 





2.3.4 Target Gene Expression 
Compared to SSC and LSC at the same passages, induced P0 and P3 ASC had 
significantly higher mRNA levels of peroxisome proliferator-activated receptor 
gamma (PPAR-γ) and leptin following adipogenic induction, osteoprotegerin (OPG) 
and collagen 1 (Col1) following osteogenic induction, and aggrecan following 
chondrogenic induction (See A-F in Figure 2).  Following adipogenic and osteogenic 
induction, P0 and P3 ASC had significantly lower mRNA levels of homeobox protein 
nanog (Nanog) than SSC and LSC, and the same was true for sex determining region 
Y-box 2 (Sox2) expression following adipogenic induction.  There were significantly 
lower mRNA levels of Sox2 in P3 ASC compared to LSC and SSC following 
osteogenic induction.   
2.3.5 Immunophenotype 
The majority of P0 and P3 cells were CD29+, CD44+, CD90+, CD34- and CD45- 
(Figure 3), and the SVF of all cell types had lower percentages of CD44+ and CD90+ 
cells than P0 and 3 (See A-C in Figure 4).  The SSC and LSC SVF had higher CD34+ 
percentages than the ASC SVF (See D in Figure 4).  With increasing passages, the 
percentages of CD34+, CD29+, CD44+, and CD90+ cells tended to decrease in all cell 
types, while the percentages of CD45+ cells remained relatively constant (See E-H in 
Figure 4).  Among cell types, the P0 ASC CD29+ percentage was significantly higher 
than the LSC (See A in Figure 4).  The P3 ASC and SSC CD29+ percentages were 
significantly higher than LSC, and P6 ASC percentage significantly higher than SSC 
(See B in Figure 4).  The CD44+ percentage was significantly higher for P3 SSC than 
ASC, though the P6 ASC percentage was significantly higher than P6 SSC.  The P6 
ASC CD90+ percentage was significantly higher than P6 SSC (See C in Figure 4).  As 





Figure 2 Fold change (mean ± SEM, n=6, 3 replicates) of adipogenic (A, B), 
osteogenic (C, D), and chondrogenic (E, F) target genes in ASC, SSC and LSC 
Values were normalized to GAPDH and relative to cells cultured in stromal medium.  
The fold change of MSC target genes (G, H) was evaluated for each cell type 
similarly following adipogenic and osteogenic induction.  Columns with different 



















































































































































































































Figure 3 Representative immunophenotyping of SVF, P0, P3, and P6 ASC, SSC, and 
LSC 
Columns are different passages and rows different surface makers. The black graphs 





















Figure 4 Cell percentages (mean ± SEM) of P0, 3, and 6 ASC, SSC, and LSC that 
were CD29+, CD44+, CD90+, CD34-, or CD45-   
Columns with different letters within passages are significantly different from each 



















































































































































































































Stromal cell-mediated tissue regeneration is a promising approach for a wide range of 
medical applications.  We have established the IFP as the optimum source of MSC in 
the canine stifle among those evaluated.  Consistent with the hypothesis, the MSC 
population, in vitro expansion rates, and multipotentiality were highest in ASCs 
compared to SSCs and LSCs within individuals up to P6 based on cell doublings, 
CFU frequencies, MSC immunophenotypes, and target gene expression.  As passages 
increased, cell doublings, CFU frequencies, MSC immunophenotypes, as well as 
MSC, adipogenic and osteogenic lineage-specific gene expression decreased in all 
three cell types, suggesting some reduction in MSC numbers and multipotentiality.  
Notably, the ASCs retained these characteristics the best through multiple cell 
passages.  This information surrounding intra-articular MSCs may contribute to 
studies aimed at clinical translation of stromal cell technology.  
Most stifle tissues are derived from interzonal mesenchyme, so MSCs derived 
from these tissues may share common features which are distinct from those residing 
elsewhere [17].  Orthotopic cell sources have advantages for intra-articular tissue 
regeneration based on in vitro differentiation studies, possibly a result of exposure to 
the local joint environment during development potentiating cell differentiation into 
specialized joint tissues [11, 21, 177].  Multipotent cell numbers, expansion capacity 
and multipotentiality vary among the different tissues that contain MSCs within the 
femorotibial joint such as IFP, synovium, synovial fluid, and CrCL [22, 169]. We 
sought to identify and establish the best MSC source for stifle-specific tissue 
regeneration by comparing some major intra-articular cell sources within individuals. 
The ASC DT in this study was similar to previous reports for canine IFP and 




LSCs in this study were significantly lower than that those reported for human SSCs 
and LSCs [180].  In addition to species differences, the human LSCs were harvested 
from the anterior cruciate ligament (ACL) core minus synovium, collagenase 
digestion was not performed and a different culture medium was used.  Hence, 
differences in results between the studies are not unexpected.  In this study, 
decreasing cell doubling capacity with increasing passages in all cell types suggests 
that intra-articular MSCs from early passages may have the best expansion potential 
to meet therapeutic needs.  
The ASC stromal, osteogenic, and adipogenic CFU frequencies in this study 
were higher than previously reported for dogs [174].   Differences may be because of 
the use of fresh versus revitalized cells.   Indomethacin in the adipogenic medium in 
this study may have also contributed to higher CFU-Ad frequencies over the previous 
canine study (975.7±125.3) [181].   The higher adipogenic capacity of ASCs may also 
be due to a native preadipocyte population in P0 [182].   However, preadipocytes and 
multipotent cells are distinguished by the short preadipocyte lifespan in contrast to 
high expansion capacity and multipotentiality retained by MSCs through passages, so 
preadipocytes are unlikely to have affected later passages [111].  Canine IFP ASCs 
have been reported to have similar osteogenic capacity to bone marrow-derived 
stromal cells (BMSCs), which supports the superior osteogenesis of the ASCs 
compared SSCs and LSCs in this study [174].  Information surrounding direct 
comparisons of the chondrogenic potential of stifle joint tissues is limited, but rat 
SSCs reportedly have better chondrogenic potential than MSCs from subcutaneous fat 
[183].  Additionally, IFP ASCs had better chondrogenic potential than BMSCs and 
subcutaneous ASCs in elderly humans with osteoarthritis [184].  Though there was no 




study, higher mRNA levels of Col2 and aggrecan mRNA in ASC pellets may indicate 
higher chondrogenic potential.   
The identity of the MSC populations within each tissue was confirmed, in part, 
by the presence of common MSC cell surface markers detected with flow cytometry.  
The mRNA levels of embryonic stromal cell markers previously used to identify 
canine MSCs in adult tissue, Nanog and Sox2, also supported the MSC identity of cell 
populations isolated from all three intra-articular tissues in this study [24].  Cluster of 
differentiation (CD), also called cluster of determinants, are clusters of antigens that 
react with antibodies associated with various cell characteristics.  They were 
originally used to identify different stages of lymphocyte maturation, but profiling of 
CD cell surface antigen expression with flow cytometry is now a standard mechanism 
by which MSC phenotypes are distinguished.  The CD34+ cells within the SVF are 
consistent with human subcutaneous ASCs [185].  Type B synoviocytes (fibroblast-
like) are also CD34+ [186].  Since the LSCs were harvested from synovium around 
the ligament, it is reasonable that the SVF of LSCs as well as SSCs contained higher 
percentages of CD34+ cells.  Plastic adherence appeared to effectively select against 
CD34+ cells with increasing passages.  
The location, size, accessibility, and protective synovial capsule of the IFP 
make it a good potential MSC harvest option [174].  It may be feasible to isolate cells 
for reapplication prior to closure during standard surgical procedures.  Additionally, 
cells may be expanded in vitro and banked for later application.  The number of 
autologous MSC harvested from the synovium or CrCL in a diseased or injured stifle 
may be limited since synovium undergoes significant pathogenic changes in the 
presence of inflammation, and the CrCL is often partially or completely ruptured in 




potential MSC sources for tissue-specific engineering since they may contain less 
primitive cells than the IFP.  Further research is necessary to identify and confirm this 
possibility. 
The IFP is encapsulated and separated from the joint by synovium [188].  
Hence, MSCs niches within the IFP may therefore contain cells that receive less 
stimulation to induce differentiation and therefore remain more primitive compared to 
other intra-articular niches [179, 189].  Human IFP ASCs from osteoarthritic knees 
have comparable long-term cell expansion, multipotentiality, and MSC marker-
expression as normal BMSCs [190].  This is distinct from intra-articular SSCs, 
BMSCs and cartilage-derived stromal cells, where cell morphology, proliferation, and 
multipotentiality are negatively affected by acute and chronic inflammation as well as 
the presence of OA [104, 191, 192].  The results of this study suggest that the IFP is 
the optimum tissue source for adult MSC isolation in the canine stifle compared to 
joint capsular or ACL synovium.  The orthotopic advantages as well as the relative 
isolation of MSCs within the IFP in the face of injury or disease further supports the 
advantages of this tissue source.  Study findings are limited to normal tissues, and 
additional studies are necessary to confirm them in abnormal joints with distinctions 
between those affected by injury versus degenerative changes.  In conclusion, this 
side by side comparison of canine stifle joint tissue sources establishes the IFP as 
having the highest cell density and MSCs with the highest expansion capacity, 






CHAPTER 3. ISOLATION AND CHARACTERIZATION OF FRESH AND 
REVITALIZED MULTIPOTENT CELLS FROM EXCISED FELINE 
ADIPOSE 
3.1 Introduction 
Adult multipotent stromal (stem) cells (MSCs) are gaining popularity in veterinary 
medicine due to their differentiation potential, immune privilege, and sustainability in 
culture [193].  The therapeutic effects of MSCs are thought to be, in part, due to their 
release of trophic and immunomodulatory factors [62, 194].  Of companion animal 
species, stromal cell therapy has been applied in dogs and horses, but comparably few 
MSC investigations have been performed with cat tissues [150, 195-197].  Most 
feline-specific MSC reports surround BMSCs, which are reported to have both 
neurogenic and cardiogenic capacities [25, 198-200].  Additionally, intra-renal 
injection of BMSCs and ASCs for chronic kidney disease has had promising results 
[151].  Feline inguinal ASCs have higher proliferative rates in vitro than BMSCs, one 
of the many attributes that make adipose an appealing source of MSCs [201].   
In addition to those mentioned above, there are numerous pathological 
conditions in the cat that may benefit from ASC therapy.  Potential targets include 
complications associated with diabetes mellitus, lymphoma, and retinal disease which 
affect between 0.2% and 2% cats in the United States [202-205].  There are reports of 
canine and human MSC therapies for these conditions at doses of 0.5 to 50 million 
MSCs/kg [202-205]. Prior to clinical application, heterogeneous MSC isolates should 
be thoroughly characterized to meet a minimum standard of care.  At present, there 
are few tools to meet the standards of the International Society for Cell Therapy with 
feline MSCs [18].  Mechanisms to characterize feline MSCs are necessary for clinical 




 Adipose-derived stromal cells can be isolated from both white adipose tissue 
(WAT) and brown adipose tissue (BAT).  As a highly active metabolic tissue, WAT 
contains a large number of stromal vascular cells with great differentiation potential 
[206, 207].  Since epididymal adipose harvested during routine feline castration is one 
of the purest sources of WAT it is a promising tissue for ASC harvest [208].  
According to the 2011-2012 National Pet Owners’ Survey by the American Pet 
Products Association, 88% of approximately 86.4 million privately owned cats in the 
United States are spayed or neutered. ASCs harvested from tissue excised during 
neutering may be expanded in vitro and applied in the short term or cryopreserved for 
later application.  Based on current information, therapeutic doses of MSCs range 
from 105 to 108 cells/kg.  The differentiation potential and expansion rate of ASCs 
decreases with increasing passages in most species, and the cells tend to have the 
highest multipotentiality before P4 [174].  Based on results from other species, 0.5 ~ 2 
x 106 nucleated cells can be expanded from one gram of inguinal or epididymal 
adipose tissue with a colony forming unit frequency of 1% to 10% [150, 209-211].  
Cell doubling times for most species are approximately two days before P4 [174, 212].  
Based on broad assumptions from the published literature in other species, 
approximately 2 ~ 3 g of feline epididymal adipose would be needed to yield 106 
nucleated cells/g containing 104 ASCs to provide a dose of 107 ASCs within three cell 
passages.  Our objective was to optimize ASC isolation and expansion so that 
therapeutic doses of ASCs can be harvested from individual cats based on the 
hypothesis that 107-108 ASCs are available within 3-4 cell passages to give an MSC 






3.2.1 Study Design  
Epididymal tissue was collected during routine castration of 14 male domestic short 
hair cats (1.0 ± 0.2 years, 2.9 ± 0.3 Kg, mean ± SEM).  The body conditioning score 
of the cats included in this study were around 4 – 6 on a scale of 1 – 9.  Cell 
expansion rate, multipotentiality and progenitor cell surface markers were evaluated 
for both fresh and revitalized (cryopreserved for 1 month) cells from individual cats 
as follows: P0-5 cell doublings (CD) and doubling times (DT); P0, 1, 3 and 5 CD29+, 
CD44+, CD90+, CD34+, and CD45+ cell percentages; P0, 1, 3 and 5 colony forming 
unit (CFU) -fibroblastic (F), adipogenic (Ad) and osteogenic (Ob) frequencies; P1 and 
3 stromal and induced (adipogenic, osteogenic, and chondrogenic) cell MSC and 
lineage specific target gene mRNA levels.  Fresh cells from each cat were further 
assessed: P0 chondrogenic pellet alcian blue (proteoglycan) staining; stromal vascular 
fraction (SVF), P0, 1 and 3 F-actin and Hoechst dye staining.  The SVF CFU-F 
frequencies were also determined using pooled tissue from 10 other male domestic 
short hair cats to meet adequate cell numbers for seeding. 
3.2.2 Materials 
All reagents were purchased from Sigma Chemical Co. (St. Louis, MO) or Fisher 
Scientific (Dallas, TX) unless noted otherwise. 
3.2.3 Isolation Method 
Epididymal adipose was harvested, and tissue was processed within 4 hrs of harvest 
for each cat.  Adipose tissue was isolated with sharp dissection, minced, and digested 




The isolation method was first discovered using tissues from 5 cats.  Tissues 
from the rest 9 cats were all digested with the best method.  Tissues from each cat 
(n=5) were divided into three equal portions, and each portion was digested by one of 
three methods:  1) 0.3% type I collagenase in Kreb’s Ringer buffer, 0.5 hr, 1000 rpm 
stirring (New); 2) 0.3% type I collagenase in Kreb’s Ringer buffer, 1 hr, 1000 rpm 
stirring (Hour); and 3) 0.1% type I collagenase in DMEM, 0.5 hr, 60 rpm (Classic).  
The digestion solution was then filtered (100 µm, BD Falcon, Bedford, MA).  The 
resulting pellet (260 g, 5 min) was resuspended in 5 ml red cell lysis buffer (0.16 
mol/L NH4Cl, 0.01 mol/L KHCO3, 0.01% EDTA).  The resulting SVF was seeded in 
a 10 mm cell culture dish (CellStar, Greiner, NC) in stromal medium (DMEM-Ham’s 
F12, 10% fetal bovine serum (FBS), 1% antibiotic/antimycotic solution) and cultured 
under standard conditions (37°C, 5% CO2).  Medium was refreshed after overnight 
incubation and then every 2-3 days.  When the first colony that contained > 20 cells 
was discovered, the number of colonies was counted.  MSC density was calculated as 
colony number/adipose weight (g).  The new method was selected to isolate ASCs for 
the remainder of the study based on the highest number of colonies/g epididymal 
adipose.  For purposes of this study, primary cell isolates were considered the SVF 
and the first cell passage was P0. Cells were seeded at a density of 5 x 103 cells/cm2 
for P0 and all subsequent passages for all assays.   
3.2.4 Cell Expansion 
P0 cells were seeded in 12-well plates and counted after 2, 4, and 6 days of culture.  
Cell doublings and DT were determined with duplicate cultures and calculated with 
the formulae: CD= ln(Nf /Ni)/ln(2) DT= CT/CD (Ni: initial cell number; Nf: final cell 
number; CT=culture time) [172].  Day 2 and day 4 cell counts were used as the initial 




3.2.5 Trilineage Differentiation 
Feline-specific induction media were developed in this study.  Cells at P0 were first 
cultured in stromal medium to 80% confluence, and then transferred to adipogenic 
medium (α-MEM, 10% rabbit serum, 10% FBS, 10nM dexamethasone, 5µg/mL 
insulin, 50µM 5,8,11,14-eicosatetraynoic acid (ETYA) [Cayman, Ann Arbor, MI], 
100µM indomethacin) for 10 days.  Cells were fixed with 4% paraformaldehyde (PFA) 
and stained with Oil Red O.  Confluent P0 cells were also cultured in osteogenic 
medium (DMEM, 10% FBS, 100 nM dexamethasone, 0.25 mM L-ascorbic acid) for 
10 days and then in osteogenic medium supplemented with 10nM β-glycerophosphate 
for another 10 days to avoid delamination.  Cells were fixed in 70% ethanol and 
stained with 2% alizarin red.  For chondrogenesis, 5 x 105 cells were centrifuged (200 
x g, 5 min) to form a pellet in a 15 ml tube (Corning, NY).  The pellet was cultured in 
chondrogenic differentiation medium (Low glucose DMEM-Ham’s F12, 1% FBS, 1% 
antibiotic/antimycotic solution, 50 µg/mL ascorbate phosphate, 100 nM 
dexamethasone, 40 µg/mL proline, 1 mM sodium pyruvate, 1% ITS, 10 ng/mL BMP-
6, 10 ng/mL TGF- β1) for 21 days.  Cell pellets were cultured in stromal medium for 
comparison.  At the end of the culture period, pellets were formalin-fixed, paraffin-
embedded, sectioned (5 µm) and stained with alcian blue.   
3.2.6 Multipotentiality (SVF, P0, 3, 6) 
Limiting-dilution assays to determine CFU-F, -Ad and -Ob frequencies were 
performed as previously reported with changes indicated [174]. Due to the low ASC 
density in the SVF, samples were pooled from 10 unrelated cats, and 8 replicates of 
500, 250, 125, 63, 31, or 16 cells were seeded for CFU-F.  For P0, 1, 3, and 5, 8 
replicates of 5 x 103, 2.5 x 103, 1.25 x 103, 6.25 x 102, 3.12 x 102, or 1.56 x 102 




10 days.  The CFU-F colonies were fixed with 4% PFA and stained with 0.1% 
toluidine blue.  For CFU-Ad and -Ob, cells were cultured in lineage-specific induction 
media as described above, and the number of stained colonies in each well was 
counted. Wells were considered positive for fibroblast-like colonies, adipogenesis, or 
osteogenesis when there were ≥10 toluidine blue-stained colonies, ≥10 oil red O-
stained colonies, or ≥1 alizarin red-stained colonies, respectively.  The CFU 
frequencies were calculated as F=e-x (F: ratio of negative to total wells within a row, e: 
natural logarithm constant 2.71, x: CFU number per well).  Based on Poisson’s 
distribution, F = 0.37 occurs when the number of total cells plated (N) in a well 
contains a single CFU.  The CFU frequency is reported as 100 / N %. 
3.2.7 Immunophenotypes (P0, 1, 3, 6) 
Cell aliquots (105 - 106) were resuspended in 200 ml PBS containing 5 µl of antibody.  
Cells were incubated with antibodies specific for feline antigens or validated for feline 
cross reactivity for 30 min at room temperature (Table 6).  The cells were then 
washed with PBS and fixed with 4% PFA.  For CD9, CD29, CD44, and CD90 
samples, indirect immunofluorescence was done with goat anti-mouse IgG-FITC.  For 
negative autofluorescence control, cells were not incubated with antibodies.  Cellular 
fluorescence was evaluated by flow cytometry using a FACSCalibur flow cytometer 
and CellQuest Pro software (BD Biosciences).  Cell percentages expressing each 
antigen were determined using population gated of fluorescence subtracting relative 
autofluorescence control.   
3.2.8 Cell Morphology (SVF, P0, 1, 3)  
Cells were cultured in stromal medium on glass coverslips for 7 days.  Cells were 
washed with PBS, fixed in 4% PFA for 20 min, permeablized with 0.5% Triton-x100 




Hoechst dye (1:2000) for 5min at RT.  Samples were then viewed with a fluorescence 
microscope DM4500B (Leica, Buffalo Grove, IL). 





Species Manufacturer Cat No. Marker Specification 
CD9 N/A Cat Serotec MCA1345 Myeloid 
CD29 N/A Human BD Biosciences 610468 Cell adhesion, β1 integrin 
CD44 N/A Cat VMRD BAG40A Hyaluronic acid receptor 
CD90 N/A Human eBiosciences 14-0909-80 Thy-1, fibroblasts, MSC 
CD105 PE Human eBiosciences 12-1057-41 
Endoglin, mesenchymal, 
and erythroid progenitors 
IgG FITC Mouse Sigma-Aldrich F9006 Goat anti-mouse IgG 
3.2.9 Expression of marker genes (P1, 3) 
Total RNA was extracted from cells using TRIzol reagent (Fisher) according to the 
manufacturer’s instructions.  Quantity was determined with a ND-100 
spectrophotometer (NanoDrop Technologies, Wilmington, DE), and 1 µg of RNA was 
used for cDNA synthesis per 20 µl reaction using a QuantiTect Reverse Transcription 
Kit (Qiagen, Hilden, Germany). Feline-specific primers were used for all reactions 
(Table 7). qRT-PCR was performed in duplicate with a 20 µl total reaction using a 
QuantiTect SYBR Green PCR Kit (Qiagen), 0.3 µM for each forward and reverse 
primer in a 384 well PCR plate.  PCR amplication was performed using Applied 
BioSystems 7900 Real-Time PCR System (SDS v2.4; Applied Biosystems, Carlsbad, 
CA) and stoped at 40 cycles according to the manufacturer’s program.  In the present 
study, the data are presented as the fold change in target gene expression in 
differentiated cells normalized to glyceraldehyde 3-phosphate dehydrogenase 




Table 7 Feline-specific primer sequences 
 Gene Forward Primer Reverse Primer 




























Nanog GATCTCCTCTGCAGAAGTGG  
CTCCAGTGCCTGAGA
TTGATGG 
PPAR-γ, peroxisome proliferator-activated receptor gamma; Col1, collagen type I; 
OPG, osteoprotegerin; Col2, collagen type II; Sox2, sex determining region Y-box 2; 
Nanog, homeobox protein nanog. 
3.2.10 Statistical Analysis  
All results are presented as mean ± SEM.  Among passages, differences in CD, DT, 
CFU frequency, RNA levels and cell surface marker percentages were determined 
with one-way ANOVA and Tukey’s post hoc tests (P<0.05) using SAS.   
3.3 Results 
3.3.1 Isolation Method  
A mean of 0.2 ± 0.03g (wet weight) adipose was harvested from each cat.  The Hour 
and Classic isolation methods yielded 3.8 and 1.6 colonies/g, respectively, which 
were not significantly different.  The New isolation method had a higher yield of 
126.3 ± 33.9 colonies/g with tissues from five cats (see A in Figure 5).  Using tissues 




significantly different that the finding with five cats (see B in Figure 5).  At 80% 
confluence, there were about 1 x 106 P0 cells per 10 cm dish for P0-2.  With a 
consistent seeding density of 5 x 103 cells/cm2, around 2 x 107 cells are available by 
P2, which is 7 x 106 cells/kg for the cats in this study. 
 
Figure 5 Feline epididymal adipose ASC isolation method 
(A) Feline epididymal adipose ASC yields using three different digestion techniques 
(n=5).  (B) ASC yield using the new digestion method (n=15). 
3.3.2 Cell Morphology 
Five days after seeding, adherent SVF cells showed a spindle-shaped morphology 
typical of ASCs (see A in Figure 6). Homogenous cultures and elongated shaped cells 
increased at P0 and 1 (see B,C in Figure 6), which became flattened and disorganized 
by P3 (see D in Figure 6).  
 
Figure 6 Feline ASC morphology 
Cells of SVF (A), P0 (B), P1 (C) and P3 (D) were stained with FITC-F-actin (green) 




































3.3.3 Cell Expansion 
The overall CD for P0-5 fresh cells was 0.7 ± 0.1 CD/days, and the corresponding DT 
was 1.4 ± 0.2 days/CD. Generally, cell expansion rates decreased as passages 
increased.  For fresh cells, P0-2 cells had significantly higher CD than P3-5 (Table 8), 
while P0-3 cells had significantly lower DT than P4 and 5 (Table 9).  For revitalized 
cells, P1 and 2 cells had significantly higher CD than P3-5, and P1-3 cells had 
significantly lower DT than P4 and 5.  Fresh cells at P4 and 5 had significantly higher 
CD and lower DT than revitalized cells. 
Table 8 Fresh and revitalized feline ASC cell doublings (CDs/day) for P0-5 (mean ± 
SEM) 
 P0 P1 P2 P3 P4 P5 
Fresh 1.3±0.1a 1.1±0.1b 0.9±0.1b 0.5±0.04c 0.3±0.02c 0.3±0.04*,c 
Revitalized  1.1±0.1
a 0.9±0.1a 0.5±0.03b 0.2±0.02c 0.1±0.01c 
Values within columns with asterisks are significantly different from revitalized cells.  
Values with different lower-case letters within passages (columns) are significantly 
different (p<0.05). 
 
Table 9 Fresh and revitalized feline ASC doubling times (days/CD) for P0-5 (mean ± 
SEM) 
 P0 P1 P2 P3 P4 P5 
Fresh 0.8±0.2a 0.9±0.2a 1.1±0.2a 2.0±0.4a 3.3±0.6*,b 3.3±1.2*,b 
Revitalized  0.9±0.1
a 1.1±0.2a 2.0±0.4a 5.0±1.6b 10.0±1.2c 
Values within columns with asterisks are significantly different from revitalized cells.  
Values with different lower-case letters within passages (columns) are significantly 
different (p<0.05). 
3.3.4 Trilineage Differentiation  
After about four days of culture in adipogenic medium, cells became round, and, after 
21 days, robust lipid droplets were apparent (see A in Figure 7).  In osteogenic 
medium without β-glycerophosphate, cells assumed a compact, cuboidal appearance 
and expressed alkaline phosphatase (ALP) after 10 days of culture (see B in Figure 7).  




with alizarin red (calcium deposition) after 21 days of culture (see C in Figure 7).  
Cells were apparent within lacunae in pellets cultured in chondrogenic induction 
medium after 21 days, and extra-cellular matrix stained with alcian blue (unsulfated 
proteoglycan) (see D in Figure 7).  Pellets cultured in stromal medium did not show 
lacunae formation (see E in Figure 7). 
 
Figure 7 Feline ASC trilineage differentiation 
(A) ASC adipogenesis.  Lipid droplets were stained with oil red O after 10 days 
induction (40x).  (B) Early stage osteogenesis.  Alkaline phosphatase (ALP) was 
stained by 5-Bromo-4-chloro-3-indolyl phosphate/ nitro blue tetrazolium chloride 
after 10 days induction (10x).  (C) Late stage osteogenesis.  Extracellular matrix 
calcium was stained by alizarin red after 20 days induction (5x).  (D) Early stage 
chondrogenesis.  Cell pellet was stained with alcian blue after 20 days culture in 
induction or stromal medium (E) (64x).   
3.3.5 Multipotentiality  
The CFU frequency indicates the percentage of cells within a population that are 
capable of forming CFU-F, -Ad or -Ob colonies.  Due to low expansion rates after P3, 
P5 revitalized cells were not included in CFU assays.  The SVF CFU-F frequency was 
1.6% (Table 10).  Fresh cells at P0 and 1 had significantly higher CFU-F, -Ad, and -
Ob frequencies than P3 and 5.  Revitalized P1 cells had significantly higher CFU-F, -
Ad, and -Ob frequencies than P3.  Also, fresh P3 cells had significantly higher CFU-F 




Table 10 Colony forming unit (CFU) frequencies (mean ± SEM) for fresh and 
revitalized feline ASCs 
CFU Frequencies (%, mean ± SEM) 
Passage Cell type CFU-F (%) CFU-Ad (%) CFU-Ob (%) 
SVF Fresh 1.6   
0 Fresh 2.2±0.2a 0.3±0.02a 0.7±0.2a 
1 
Fresh 2.0±0.7a 0.3±0.08a 0.6±0.04a 
Revitalized 1.9±0.4a 0.3±0.03a 0.5±0.1a 
3 
Fresh 0.1±0.01*,b 0.03±0.01b 0.1±0.01*,b 
Revitalized 0.04±0.01b 0.02±0.01b 0.03±0.03b 
5 Fresh 0.02±0.005c 0.002±0.002c 0.01±0.01c 
Values with asterisks are significantly different from revitalized cells within passage 
and CFU.  Values with different lower-case letters within passages are significantly 
different. 
3.3.6 Immunophenotypes 
The majority of P0, 1, 3, and 5 cells were CD9+, CD29+, CD44+, CD90+, and CD105+, 
and there were no differences between new and classic isolation methods (Figure 8).  
 
Figure 8 Representative immunophenotyping of P0 feline ASCs isolated using the 
new and classic methods   








Using the new method, P0 had significantly fewer CD105+ cells than P1, while P5 
cells had significantly fewer CD9+ and CD105+ cells than P0 and 1 (See A in Figure 
9).  There were significantly more CD29+ cells at P1 and 3 than P5.  Revitalized P3 
cells had significantly more CD9+ and CD105+ cells than P1 (See B in Figure 9). 
 
Figure 9 Cell percentages (mean ± SEM) of P0, 1, 3, and 5 fresh (F) and revitalized 
(R) ASCs positive for CD9, CD29, CD44, CD90, or CD105   
Columns with different letters within markers are significantly different from each 
other (P < 0.05).   
3.3.7 Expression of marker genes 
Compared to P3 cells, induced P1 cells had significantly higher mRNA levels of 
peroxisome proliferator-activated receptor gamma (PPAR-γ) and leptin following 
adipogenic induction for both fresh and revitalized populations (See A,B in Figure 10).  
Both fresh and revitalized P1 cells following osteogenic induction also had 
significantly higher mRNA levels of osteoprotegerin (OPG) and collagen 1α1 
(Col1α1) (See C,D in Figure 10).  Both fresh and revitalized P1 cells after adipogenic 
or osteogenic induction had significantly higher levels of Sox2 than P3 (See E in 
Figure 10).  Revitalized adipogenic P1 cells had significantly higher levels of Nanog 
than P3 (See Fin Figure 10).  Also, fresh adipogenic P3 cells had significantly higher 
Nanog levels than revitalized cells.  Additionally, both fresh and revitalized P1 cells 





































































Figure 10 Fold change (mean ± SEM, n=5) of adipogenic and osteogenic target gene 
mRNA levels in feline ASCs 
ASCs following adipogenic or osteogenic induction were compared to parallel 
cultures maintained in stromal medium Columns with different letters within markers 
are significantly different from each other (P < 0.05).  Columns with asterisks are 
significantly different from revitalized cells.   
3.4 Discussion 
Stromal cell therapies may be an option for numerous feline pathologies.  An efficient 
method to isolate ASC from feline epididymal adipose was developed in this study.  
Consistent with the hypothesis, a therapeutic dose of ASC was available within three 























































































































































Decreasing cell expansion, multipotentiality and MSC immunophenotype with 
increasing passages suggests that early passages of fresh or revitalized feline 
epididymal ASCs from have the greatest potential for therapeutic benefit.  Hence, 
ASCs can be harvested from tissue that is routinely discarded and preserved for later 
administration, obviating the need for additional surgery or potential risks of 
allogenous cells.  Further, the techniques to identify MSC surface marker expression 
in this study benefit efforts to isolate homogenous ASC populations for 
characterization and expansion.  
There are several advantages to using epididymal adipose tissue for ASC 
isolation.  It is a deposit of pure WAT in contrast to subcutaneous adipose tissue, a 
combination of BAT and WAT [207, 208].  White adipose tissue contains a higher 
ASC density compared to BAT [207].  Further, most cats are castrated as young 
animals.  Numerous studies support the higher density and greater multipotentiality of 
ASC harvested from young versus older donors [213-215].  Cell banking for later 
administration is a feasible approach to address the consequences of aging in feline 
companions.  While the results of this study are currently limited to toms, it is logical 
to extend this work to adipose tissue removed during routine spay procedures on 
queens. 
Despite promising early results from clinical application in a number of 
species including cats (Table 11), standard protocols for ASC isolation, expansion and 
clinical application are lacking.  Cell isolates are by nature heterogeneous and contain 
adipocyte precursors, mature endothelial cells, haematopoietic cell populations and 
tissue-specific progenitor cells [111].  Further, isolation procedures are generally 
customized for different adipose tissue harvest sites [216].  Significant variability 




Table 11 Therapeutic applications of MSCs 
Trial Species Source Treatment Results 
Chronic kidney 
disease [151] Feline 




2 of 4 cats with mild 
increase in 
glomerular filtration 





1.47 x 106 
ASC SVF/kg Intrarenal 
Creatinine improved 
3.8%, BUN improved 
19.6% 
Type I diabetes 
[218] Canine 













Normal levels of 
serum thymidine 
kinase and the 
absence of peripheral 








Ceramic carrier Enhanced bone formation 
Meniscus 
defects[48] Caprine 10














function and reduced 
size of infarct scar 
Type I diabetes 
[217, 223-225] Human 





biological marker and 
no adverse effects 
Type I diabetes 
[226, 227] Human 





Type II diabetes 
[228-230] Human 


















Though inherent individual variability among animals cannot be avoided, 
standardized isolation and characterization techniques for specific adipose deposits 
may significantly enhance the predictability of ASC behaviour and efficacy following 
administration.  The efficient, repeatable ASC isolation technique from feline 
epididymal tissue established in this investigation is an option toward this goal.  
Further, selection of ASC by surface marker expression may likely increase 
consistency in in vitro and in vivo behaviour [99, 232].   
The amount of adipose tissue available from excised castration tissue is about 
a tenth of that typically harvested from other adipose depots [233].  Despite this, a 
“dose” of cells was available within three cell passages in this study, using plastic 
affinity to select for ASCs [234].  Inconsistent cell expansion can contribute to 
differences among cell isolates since extensively expanded cells are technically “older” 
than those that have been expanded as much [235].  While SVF colony numbers were 
relatively low in this study, they were not significantly different among animals.  
Further, cell seeding density was identical for all cell passages.  Given the age at 
which most of the cells will likely be isolated, they could be applied for congenital 
conditions, chronic illness or later for age related problems.  Thus, the expansion time 
necessary for a characterized epididymal ASC isolate is unlikely to restrict use. 
Kreb’s ringer buffer contains 4-5 fold fewer nutrients than DMEM.  It was 
used for collagenase digestion since DMEM components like high glucose and 
sulfhydryl and chelator-containing amino acids inhibit collagenase activity [236-239].  
Mechanical agitation and lengthened digestion times were applied to promote tissue 
dissociation and facilitate collagenase activity, both of which can decrease cell 
viability [240, 241].  Study findings including cell phenotype, morphology, CD and 




confirming that the vigorous digestion did not inhibit subsequent cell function [25, 
151, 172, 174, 193, 210, 234, 242].  The significant increase in CD105+ cell 
percentages from P0 to P1 is consistent with ASC selection by plastic adherence [243, 
244].  Decreased CD9+ and CD105+ cell percentages in late cell passages parallel the 
observed reductions in multipotentiality based on CFU-Ad and -Ob frequencies and 
tissue specific mRNA levels.  
Differentiation media used in this study were optimized for feline ASC based 
on existing knowledge from other species [25, 151, 174].  Adipogenesis induction 
medium contained ETYA and indomethacin which promote lipid droplet formation 
by PPAR-γ activation, and rabbit serum, a component of canine and equine ASC 
adipogenic medium [25, 163, 181, 226].  Beta-glycerophosphate was added to 
osteogenic medium after 10 days of culture to avoid colony delamination [245].  For 
chondrogenesis, bone morphogenetic protein-6 was added to enhance proteoglycan 
synthesis as reported for equine MSC [163, 246, 247].  The induction media used in 
this study may be valuable for future feline ASC studies, especially in the area of in 
vitro tissue generation. 
Results from the present study demonstrate that tissue excised from routine 
castration is a reliable source of feline ASCs.  The New method of adipose tissue 
digestion results in a therapeutic dose of functional ASCs for potential autologous 
administration.  Cell cryopreservation is a mechanism to maintain potent ASCs for 
later application that will reduce cell expansion time and avoid tissue harvest from 
sick or injured patients.  Use of MSC surface antigens and major histocompatibility 
markers to isolate homogenous ASC populations is a natural extension of the work 
reported here that may enhance cell efficacy and reduce the potential for rejection or 




standard of care, standardized isolation and administration protocols as well as safety 
and efficacy, should be established with preclinical investigations and randomized, 





























CHAPTER 4. IN VITRO CANINE CRANIAL CRUCIATE LIGAMENT 
REGENERATION USING ADULT INFRAPATELLAR ADIPOSE-DERIVED 
MULTIPOTENT STROMAL CELLS, COLLAGEN SCAFFOLD AND PDS 
SUTURES 
4.1 Introduction 
4.1.1 Cranial Cruciate Ligament Disease (CrCL)   
The CrCL connects the lateral condyle of the femur and the anterior intercondylar 
area of the tibia. Rupture of the CrCL is one of the most common causes of hindlimb 
lameness in dogs. Sometimes, acute CrCL injury can occur due to trauma, when the 
dog jumps, slips, make a sudden turn or steps into a hole and the relative forces 
stressing the ligament exceed its breaking strength. However, only 20% of canine 
CrCL deficiencies are due to trauma. The majority of CrCLs rupture due to 
progressive and irreversible degeneration within the ligament itself [248, 249]. These 
non-traumatic ruptures are called spontaneous CrCL rupture.  Both partial and 
complete CrCL rupture accelerates development of osteoarthritis (OA), a highly 
prevalent and progressive degenerative joint disorder which leads to pain, stiffness 
and decreased range of movement in both animals and humans.  Age, genetic, 
conformational, environmental, immune-mediated, and inflammatory factors can 
contribute to development of OA [250-252].  
Genetics exert a direct impact on the structural properties of the CrCL.  
Labrador Retrievers, Rottweilers, and Newfoundlands have a higher risk for non-
traumatic CrCL deficiency, while Greyhounds have a relatively lower predisposition 
[253, 254].  A survey from 574 Newfoundlands showed 22% prevalence of CrCL 
deficiency and 51% penetrance in the recessive mode of inheritance [255].  A 
subsequent showed that four microsatellite markers from 4 respective chromosomes 
associated with CrCL disease were found in a subset of 90 Newfoundlands. 




Another report showed no significant differences between the gene expression 
profiles of dogs with high risk of CrCL rupture and dogs relatively resistant to the 
rupture [256]. But protease and extracellular matrix genes (aggrecan, caspase 8, 
collagen 1A2, collagen 3A1, collagen 5A1, cathepsin B, cathepsin D, insulin-like 
growth factor 1, lumican, MMP-2, MMP-9, cyclooxygenase 2, tissue inhibitor of 
metalloprotease 1, and tenascin C) had higher expression in ruptured CrCLs 
compared to intact CrCLs, suggesting involvement in ligament rupture.   
Conformational factors include both pelvic limb and stifle abnormalities.  
Genu varum (bow leggedness) is one of the most common conditions associated with 
CrCL degeneration [254]. It often appears as a poor coxofemoral conformation 
(dysplasia), femoral angulation, tibia internal rotation, proximal angulation and 
medial patellar luxation [251, 257].  Narrowed intercondylar notch (ICN) in dogs 
leads to impingement from the medial aspect of the lateral femoral condyle, or at the 
level of the intercondylar roof of the fossa [258]. Another theory is based on a 
biomechanical model developed by Slocum surrounding the tibial plateau angle [259]. 
Ground reaction forces propagate along the tibia while a shear force is generated by 
the compression of the femur against a caudally oriented tibial plateau slope.  This 
theory is also the principle for the tibial plateau leveling osteotomy (TPLO).  Patellar 
tendons also contribute to joint reaction forces [260].  The patellar tendon determines 
the alignment of the force generated by quadriceps contraction [261].  The TPLO is a 
fairly complex procedure with some potentially unrecognized pitfalls where 
iatrogenic errors can result in a change in limb angulation and rotation [262] 
In CrCL disease, both humoral and cell-mediated immune responses are 
recognized.  The structure is covered by a synovial membrane and hence protected 




the synovial fluid (SF) that stimulate autoantigenicity [263-265].  Also, COLI 
released by injured CrCL was absorbed by macrophages, which became activated and 
presented collagen as the antigen to native T cells and B cells for antibody production.  
These antibodies were further released into synovial fluid, generating immune 
complexes.  Or the collagen was phagocytositized by macrophages which began 
CrCL proteolytic degradation [266].  Need concluding statement 
A number of biochemical factors have been discovered to induce the joint 
inflammation, both pro-inflammatory and anti-inflammatory.  Different cytokines 
affect the inflammation process at different stages of the immune response.  The 
imbalance between the pro-inflammatory and anti-inflammatory factors after CrCL 
injury may cause OA occurrence, and induce the upregulation of immunoregulatory 
factors, such as cytokine inhibitors and growth factors [267].  Cytokines such as IL-
1β, IL-1rα, IL-6, IL-8, IL-10 and TNF-α are reported to be involved in CrCL injury 
[268-270].   It has also been confirmed that SF in joints with ruptured CrCLs contains 
collagen [271], glycosaminoglycan [272], proteoglycan, and fibronectin [273].  These 
particles may initiate and promote OA.   
4.1.2 CrCL Pathogenesis 
Ligament pathogenesis is a complicated series of events, including changes in 
ligament cells and extracellular matrix at molecular, biochemical, microstructural and 
macrostructural levels [274]. They share many degradative molecules with the 
initiation and progression of OA.  Matrix metalloproteinases (MMP) are reported to 
be involved in both ligament pathogenesis and initiation of OA in CrCL disease, as 
well as collagenases [275], gelatinases [276], cathepsins [277]and other degradative 
enzymes. Recently, MMP expression in stifles with normal and partially disrupted 




MMP-2 and MMP-3 in response to explant ligament media in vitro compared to 
partially disrupted ligaments after 6 days of culture.  This study confirmed the 
capacity of intact CrCLs to secret degradative enzymes when exposed to an abnormal 
environment.  Because MMP-3 is able to cleave and activate other MMPs, it is 
possible that MMP-3 plays an essential role in both CrCL pathogenesis and initiation 
of OA.  Interestingly, additional research showed that MMP-3 levels in synovial fluid 
were increased in older hounds compared to younger beagles with normal CrCLs 
[277].  Therefore, the level of MMP-3 expression can be used as a target to detect the 
occurence and condition of CrCL disease. 
4.1.3 Cranial Cruciate Ligament Repair 
Tissue repair requires coordination of a series of cellular and molecular events.  
Initially, local or undifferentiated cells start tissue repair by migrating into the injured 
area and proliferating [279].  Concurrently, physiological angiogenesis provides 
sufficient nutrients and oxygen to support cell survival.  Cells going through 
proliferation and differentiation produce new extracellular matrix (ECM) and to 
restore the structure and the function of the damaged area [280]. The challenge of 
tissue repair is creating a well-organized ECM to direct progenitor cells while 
maintaining tissue structure and strength [281]. 
Generally, cells in ligaments are renewed at a relatively slower rate than most 
soft tissues, so ligaments heal more slowly than other tissues [282].  For extra-
articular ligaments like the medial collateral ligament (MCL), spontaneous healing 
occurs in 4 phases. Phase I occurs within the first 72 hours with bleeding and 
hemostasis. The hematoma helps to bridge the torn ends. Then, in phase II, 
inflammatory cells, including monocytes, leukocytes, and macrophages aggregate, 




collagen, and type I collagen to a lesser extent. Cells proliferate and matrix deposition 
forms a vascular neo-ligament in phase III, followed by the organization of 
collagenous tissue arrangement and synthesis of higher proportion of type I collagen 
and long-term remodeling in phase IV [283]. 
In the case of CrCL repair, when the thin synovial sheath of the CrCL is 
ruptured, blood dissipates into the synovial fluid, making it difficult to form a 
localized hematoma with cytokines, growth factors, and reparative cells at the injury 
site [284, 285]. Also, because the torn components retract, there is a high residual 
strain in the intact CrCL [286].  Additionally, compared with cells derived from other 
ligaments, CrCL fibroblasts have lower mobility, proliferation and metabolic 
activities, and matrix production tendencies, poorer adhesive strength, and higher 
MMP expression [287-291].  The CrCL therefore has limited healing capabilities 
compared to other ligaments.   
A wide range of growth factors and cytokines have been reported to directly 
interact with transmembrane receptors to regulate cell functions during tissue repair  
[292]. Mechanisms are, in general, only partially described.  Platelet-derived growth 
factor (PDGF) acts as a mitogen to help connective tissue cells grow, change shape 
and motility and reorganize actin filaments.  Transforming growth factor-beta (TGF-β) 
is strongly related to morphogenicity and collagen synthesis.  Type I insulin-like 
growth factor (IGF-I) is fully involved in cell survival, growth and metabolism.  
Finally, vascular endothelial growth factor (VEGF) and hepatocyte growth factor 
induce endothelial cell proliferation and migration, and angiogenesis [293-296].  
Multiple growth factors were found to contribute to CrCL repair. Myostatin, 
also referred to as growth and differentiation factor 8 (GDF-8), is a member of the 




First, myostatin and its receptor, the type IIB activin receptor (ActRIIB), were found 
to increase cell proliferation and the expression of type I collagen in primary 
fibroblasts in the leg tendons of mice [298].  Myostatin binds theActRIIB and type I 
co-receptor (Alk4/5) to regulate the expression of downstream target genes such as 
myogenic differentiation protein (MyoD) and myogenic factor-5 (Myf-5) via a TGF-β 
signaling pathway [299]. With myostatin treatment, mouse tendon cells increase 
fibroblast proliferation and type I collagen expression [300].  Similarly, with 
myostatin treatment, proliferation, extracellular matrix synthesis and the expression of 
tenascin C (TNC), type 1 collagen and transforming growth factor-β1 increases in 
CrCLs of myostatin-deficient mice.  Additionally, compared to injured MCLs, there 
was limited expression of PDGF and TGF-β1 in injured CrCLs in rabbit CrCL and 
MCL injury models [301].  Lower expression in the CrCLs was attributed to reduced 
vascular supply. The PDGF was localized intracellularly in tenocytes and 
epitenocytes, reaching maximum levels 4 days after injury. TGF-β1 was found in 
ECM on post-injury days one and two, and decreased with time, but intracellular 
expression was increased in epitenocytes throughout the tendon and endotenocytes at 
the injury site and reached the maximum on post-injury day seven. bFGF mainly 
expressed in ECM of the tendon, but rarely in tenocytes, and reached the maximum 
on day 28 after injury.  These growth factors may be used for further analysis to study 
CrCL injury and repair. 
4.1.4 Cranial Cruciate Ligament Regeneration 
Traditional ACL repairs use biological based grafts that have good initial mechanical 
strength and promote cell and tissue growth.  However, they have a number of 
disadvantages.  Autografts from patellar hamstring or quadricep tendons are limited, 




material strength of allografts and xenografts is compromised during harvest and 
processing [127, 128].  Concerns also include disease transmission, infection and 
immune rejection [123, 124].  Tissue engineering provides a promising alternative to 
auto- and allografts.   
Adult MSCs do not express MHC II proteins, so they have immune privilege 
and can be transplanted into allogeneic hosts [302].  Also, they grow faster and 
secrete more COLI than ligament fibroblasts, and rabbit iliac crest BMSCs are 
reported to be a superior choice for CrCL regeneration compared to fibroblasts from 
the CrCL and MCL [118].  Those cells were detectable for at least 6 weeks after 
implantation.  Additionally, orthotopic MSCs have greater commitment to tissue-
specific lineages than those from heterotopic sources [167].  Intra-articular stromal 
cells showed better expansion capacity and potential for joint tissue regeneration than 
cells from other sources [177].  Species, cell passage and cryopreservation effects are 
also considerations for cell selection.  In our previous study, canine infrapatellar (IFP) 
adipose-derived stromal cells (ASCs) up to P3 had higher proliferation rates, 
differentiation potential, MSC surface marker expression and lineage-specific gene 
expression than other intra-articular MSC sources.   
As a required component in tissue regeneration engineering, a biological 
scaffold that is tailored to stem cells is central to their application for CrCL 
regeneration.  Scaffolds can be designed to stimulate and direct tissue formation in 
order to replace parts or whole tissue structures.  Scaffolds with appropriate pore size 
and microporosity (high interconnectivity between pores) can improve scaffold cell 
attachment, viability and tissue ingrowth [303].  The ideal pore diameter is around 




Scaffold material selection is important for biocompatible scaffolds.  The ideal 
replacement should possess similar physical and mechanical properties, degradability 
and structural integrity as the original tissue.  For human ACL, the scaffold should 
withstand up to 3% physiologic strains during normal knee motion [304]. 
Additionally, the material needs to resist degradation by intra-articular inflammatory 
metabolites and proteolytic enzymes, such as plasmin [305], MMP [306] and 
glycosides [307].   
Synthetic polymers are used for biocompatible scaffolds.  Many are 
biodegradable materials like poly glycolic acid (PGA), poly lactic acid (PLA), or their 
copolymers, polyurethane urea (PUU), poly desaminotyrosyl-tyrosine ethyl carbonate 
(poly (DTE carbonate)), polydioxanone (PDS) and poly caprolactone (PCL) [308, 
309].  The mechanical properties can be controlled by altering polymer concentrations, 
molecular weighst, crystallinity, structure and ratios.  For example, braided PLLA 
scaffold provides specific pore size, well-integrated pores, resistance to wear and 
rupture, and mechanical properties comparable to the human ACL [310].  Also, the 
dense connective tissue infiltrates and bonds to the braided filaments 12 weeks afater 
implantation in adult New Zealand white rabbits [311, 312]. 
Since the major component of the ACL is type I collagen (COLI), it is popular 
in ACL tissue engineering studies [313, 314].  Type I Collagen is FDA-approved and 
biocompatible, and it can be formulated as a flexible gel, sponge or fiber [315].  It 
supports MSC attachment, proliferation and migration [316].  However, it has low 
biomechanical strength and relatively high degradation rates, and the use of COLI 
alone was found ineffective in improving CrCL healing in minipigs [317, 318].  This 
indicates that COLI should be combined with other materials with stronger 




Silk is another non-cytotoxic natural polymer with good biocompatibility, 
relatively slow degradability and excellent mechanical properties [319].  It can be 
used to create a structure similar to the ACL, and both human MSCs and fibroblasts 
attach, proliferate and form ECM on silk scaffolds [320, 321].  Composite scaffolds 
of nanofibrous PLGA and silk coated with bFGF support rabbit MSC attachment, 
proliferation and ligamentocyte differentiation [322, 323]. 
Different reagents have been applied to promote CrCL healing and formation.  
Some factors included in growth medium include TGF and epidermal growth factor 
(EGF), TGF and insulin (applied sequentially), insulin-like growth factor (IGF-I), 
bFGF, VEGF, platelet-derived growth factor (PDGF), and growth and differentiation 
factor (GDF).  Platelets are activated COLI and secrete growth factors such as PDGF, 
TGF-b and VEGF[324].  Cytokine mixtures have been shown to improve cell 
proliferation but also suppress inflammation in humans [325].  A combination of 
primary suture repair and plate-concentrate resulted in greater stiffness, load at yield, 
and maximum tensile load after 4 weeks, and improved mechanical properties were 
observed as far as 14 weeks in a porcine model of CrCL wound repair [326, 327]. 
Previously, we identified the IFP to be the optimal MSC source for canine 
intra-articular tissue engineering [233].  These MSCs maintain their potency after 
cryopreservation up to passage (P) 3 [328].   Use of MSCs from healthy donors may 
have advantages of generating neo-tissue as well as immunoregulatory effects, since 
the number and differentiation potential of MSCs influences by disease and age [51, 
104, 167].  The objective of this study is to generate viable canine neoligament tissues 
from adult canine IFP ASCs on COLI CrCL templates under dynamic perfusion 
bioreactor culture conditions in vitro.  We hypothesized that canine IFP ASC 




CrCL templates will be higher with ligamentogenesis medium compared to stromal 
medium under identical perfusion bioreactor culture conditions. 
4.2 Material and Methods 
4.2.1 Study Design 
Tissue harvest procedures were approved by the Institutional Animal Care and Use 
Committee (protocol  #10-004).  The ASCs from 6 mixed breed female dogs were 
isolated from IFP immediately after tissue harvest.  Cryopreserved cell passage (P0) 
ASCs were revitalized and expanded to P3.  Canine CrCL templates were constructed 
from #2 PDS II and bovine corium COLI (AviteneTM UltrafoamTM Collagen Sponge, 
Davol Inc., subsidiary of C.R. Bard, Inc. Warwick, RI, USA).  Cells (6 x 106 
cells/scaffold) were seeded onto the templates using custom perfusion bioreactor 
chambers.  Constructs were cultured in stromal or ligament-specific induction 
medium up to 21 days with dynamic perfusion in the same chambers (2 
constructs/cell isolate/medium, 24 total).  Loading efficiency was evaluated 2 hours 
after cell seeding (n=3).  Samples (6 mm diameter) were collected 1 (upper), 2 
(middle) and 3 (lower) cm from the top of the template using a biopsy punch 
immediately after loading and 7, 14 and 21 days of culture (Table 1).  Samples were 
evaluated for cell proliferation (alamar blue), viability (calcein-ethidium bromide 
viability stain) and collagen deposition (sirus red stain).  Procollagen was quantified 
in the medium (enzyme linked immunosorbant assay), and extracellular matrix (ECM) 
and cell ultra-structure was observed (scanning electron microscopy) at the same time 
points.  Ligamentogenesis target gene expression (quantitative real-time PCR) was 
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7, 14, 21 0.06cm3 Random 1 1 
Collagen 
Deposition Sirus Red (SR) 7, 14, 21 0.06cm
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Synthesis ELISA 7, 14, 21 200ul 
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7, 14, 21 1.2 cm3 Upper half or lower half 4 1 
4.2.2 Cell Harvest, Expansion and Preservation 
The IFP adipose tissue was collected aseptically from normal stifles of six mixed 
breed female dogs (23.1 ± 0.9 kg, 3.3 ± 0.4 years, mean ± SEM).  Adipose tissue was 
minced and digested at 37°C in an equal volume of Dulbecco's Modified Eagle 
Medium (DMEM) with 1% bovine serum albumin (BSA) and 0.1% type I collagenase 
(Worthington Biochemical, Lakewood, NJ).  After washing with 1% BSA and 
centrifuging (260 g, 5 min), the resulting stromal vascular fraction (SVF) pellet was 
seeded at 5 x 103 cells/cm2 in stromal medium (DMEM-Ham’s F12, 10% fetal bovine 
serum (FBS), 1% antibiotic/antimycotic solution) followed by culture under standard 
conditions (37°C, 5% CO2).  For purposes of this study, the initial cell isolate is 
considered the stromal vascular fraction and the first cell passage is considered P0.  
Cell seeding density was 5 x 103 cells/cm2 and cell passages were performed at 80% 




106 cells/ml) in cryopreservation medium (80% fetal bovine serum (FBS), 10% 
DMEM, 10% dimethylsulfoxide) were maintained in liquid nitrogen for a minimum 
of 30 days.   
4.2.3 Immunophenotype – flow cytometry 
Following thawing (37°C, 1 min), P0 cells were cultured in stromal medium and 
expanded to P3.  Cell aliquots (P3, 5x103 cells/dog, n=6) were combined in 200 ml 
PBS and incubated with 5 µg of unlabeled CD29 (α-human, catalog #610468, BD 
Biosciences, San Jose, CA, USA), PE-CD34 (α-dog, catalog #559369, BD 
Biosciences), FITC-CD44 (α-dog, catalogue # 115440, eBiosciences, San Diego, CA, 
USA), FITC-CD45 (α-dog, catalog #125451, eBiosciences) or CD90-PE (α-dog, 
catalog #125900, eBioscience,) antibodies for 30 min at room temperature.  For CD29, 
cells were washed with phosphate buffered saline (PBS).  Indirect 
immunofluorescence was performed by incubation with goat Ig-FITC (α-mouse, 
catalogue #F9006, Sigma Aldrich, Saint Louis, MI, USA) for 30 min at room 
temperature.  Following incubation, cells were washed with PBS and fixed with 2% 
paraformaldehyde.  Surface antigen expression was determined based on comparisons 
with negative controls illustrated on 10,000 even histogram plots using a 
fluorescence-activated cell sorting flow cytometer (FACSCalibur, BD Biosciences) 
and software (CellQuest Pro, BD Biosciences). 
4.2.4 Perfusion bioreactor system 
Following revitalization and culture expansion as described above, P3 cells were 
detached with trypsin, rinsed with PBS, and resuspended in stromal medium.  Cells 
suspended in stromal medium were loaded onto templates with a perfusion bioreactor 
system (Figure 11).  Each system was composed of two custom-made bioreactors 




(Synthecon,Houston, TX) on their lowermost ends and to a peristaltic pump (Ismatec 
404b, Glattbrugg, Switzerland) on their uppermost ends with 4.8 mm inner diameter 
flexible tubing (Tygon, Compagnie de Saint-Gobain, Courbevoie, France).  The 
vessel provided oxygenation via a flat, silicone rubber gas transfer membrane.  The 
bioreactors were made of polyvinyl chloride.  One bioreactor in each system had a 
three-way stopcock at its lowermost end and a 0.22 µm syringe filter (Millipore, 
Billerica, MA, USA) between tubing attached to the bioreactor and tubing attached to 
the pump.  Both bioreactors were 50 mm in length and had a 20 mm inner diameter 
(See A-C in Figure 12).  Both ends were made with female screw locks.  Within each 
chamber was a 45 mm long structure composed of two circular ends connected by 5 
mm wide pieces (See D in Figure 12).  Across the midpoint of each circular end, a 15 
mm piece extended.  The pieces on each end were offset 90 degrees to each other.  
The ends of the template were tied to the bisecting pieces such that the figure 8 
configuration of the scaffold was maintained and the ends of the template were offset 
by about 45 degrees to replicate the CrCL structure.  Each template was pre-soaked in 
70% ethanol for 30 sec, UV sterilized for 15 min, hydrated with 10 µg/ml fibronectin 
in PBS for 30 minutes, and then tied to the frame as described above.  The frame was 
inserted into the chamber and the ends of the chambers were sealed by parafilm.  
4.2.3 PLLA: PEG scaffold construction and cell loading 
A native canine CrCL was fixed in 1% PFA for 7 days and scanned with 
NextEngine® Desktop 3D Scanner and ScanStudioTM software (NextEngine, Santa 
Monica, CA).  The 3D prototype was printed using acrylonitrile butadiene styrene 
(ABS) and casted into a polydimethyl siloxane (PDMS) mold. The scan was modified 





Figure 11 Perfusion bioreactor system 
The original perfusion system was modified with two custom-made chambers (Part I) 
and medium reservoir with gas exchange export (Part II) (C).  The system was 
connected to a peristaltic pump (Part III) and an external computer (Part IV).  The 
flow direction and rate were controlled by Labview program. 
 
America, Seattle, WA) and autoCAD were made by SolidWorks® (SolidWorks 
Waltham, WA). The PLLA (7%, wt) were dissolved in 1,4-dioxane, heated at 60°C, 
stirred for 2.5 hrs, cooled to RT, mixed with PEG (7%, wt) in a ratio of 6:4, and 
injected into the mold.  The scaffold was unidirectionally freeze dried at -88°C at a 
rate of 1.6 ml/hr for 48 hrs, and divided into 6 parts with similar sizes [329].  
All parts were gas sterilized with ethylene oxide before being assembled.  The 
system was first loaded with medium through the stopcocks towards the chambers at 




original perfusion bioreactor at a fluid flow rate of 1 ml/min for 2 hrs in an incubator.  
Flow direction was reversed after medium reached the filter so that scaffolds 
remained immersed during the loading process.  Scaffolds without cells were treated 
identically. 
 
Figure 12 Custom-designed chamber   
The chamber was 50 mm in length and had a 20 mm inner diameter and was adapted 
to the system with luer locks and a stopcock (A, C).  The inner apparatus that could be 
inserted into the chamber was used to hold the scaffold with a 45 degree twist of both 
ends (B,D).   
 After loading, constructs were transferred into a 6 well plate and cultured in 4 
types of media (10% PRP, 1% PRP, 0.1% PRP and stromal control) for up to 21 days.  
Scaffolds without cells were cultured as a negative control.  The leftover media in the 
bioreactor was collected and tubings were trypsinized.  Cell loading efficiency was 
calculated as (initial cell number – cells in the medium)/ initial cell number x 100%. 
4.2.3 Template construction and 3D culture 
The CrCL template frame was constructed using a 70 cm section of #2 PDS II in 4, 2 




with two loops of suture wrapped around the structure and tied with a square knot.  A 
5 x 4 x 0.3 cm sheet of COLI moistened slightly with PBS was wrapped around the 
frame, overlapping about 3 mm.  COLI The sponge was then saturated with medium 
causing it to shrink 30% and fit tightly to the frame.  The COL sheet was secured to 
the PDS frame with a Chinese finger trap of #2-0 Vicryl (See B in Figure 13).  Each 
template was pre-soaked in 70% ethanol for 30 sec, UV sterilized for 15 min, 
hydrated with 10 µg/ml fibronectin in PBS for 30 minutes, and then tied to the frame 
as described above.  The frame was inserted into the chamber and the ends of the 
chambers were sealed by parafilm.   
 
Figure 13 Template construction 
The PDS*II #2-0 was used to configure the shape of major bands of the CrCL (A).   
The template was wrapped by collagen I scaffold and wrapped within a Chinese 
finger trap of #2-0 Vicryl (B).  The template was secured in the inner apparatus (C).  
 
Fluid flow direction and rate were controlled by LabVIEW (v8.5, National 
Instruments Corporation, Austin, TX, USA).  Systems were primed with 48 ml 
ligament induction medium or stromal medium through the lowermost stopcock 
followed by addition of MSC suspensions (1 ml, 6 x 106 cells/template, 2.5 x 106 
cells/cm3) through the stopcock on the top of each bioreactor.  Perfusion was 
performed (37ºC, 5% CO2) at a fluid flow rate of 1 ml/min up to 21 days.  Flow 
direction was reversed after medium reached the top of a bioreactor so that scaffolds 





4.2.4 Cell viability and toxicity 
For zinc medium, 3 replicates of 1.28 x 104, 6.4 x 103, 3.2 x 103, 1.6 x 103, 8 x 102, 4 
x 102, 2 x 102, or 50 cells/well were incubated in a 96-well plate overnight in 4 types 
of zinc medium (0, 5, 10 or 20 µM ZnCl2).  The toxicity of the medium was 
determined using alamarBlue reagent (Invitrogen, Carlsbad, CA).  Cells were rinsed 
with PBS, and incubated with 10% alamarBlue™ for 4 hrs.  The fluorescence was 
measured using an excitation wavelength of 530 nm and an emission wavelength of 
590 nm using a fluorescence microplate reader (Biotek, Winooski, VT).   
The viability of cells on COLI scaffold was also evaluated using alamarBlue™.   
Samples immediately and 7 days after loading from both Zinc and stromal control 
groups were collected using a biopsy punch (6mm) from the top, medium and bottom 
area of the construct in duplicates.  Samples were further incubated with 10% 
alamarBlue for 4 hrs, aliquots (100 µL) were placed in a 96-well plate, and 
fluorescence was measured.  For growth factor medium, samples were similarly 
collected from four time points, immediately after loading, 7, 14 and 21 days of 
culture.  Cell numbers were determined on a standard curve generated from known 
cell numbers. 
4.2.5 Cell Viability – Confocal Laser Scanning Microscopy 
Samples were rinsed with PBS and incubated in darkness for 30 min at room 
temperature with 5 µM calcein and 2 µM ethidium bromide (EB) (Sigma Chemical 
Co., St. Louis, MO) in 200 µL PBS such that live cells fluoresced green while non-
viable cells fluoresced red.  A total of 20 consecutive photomicrographs (20x) of the 
entire sample cross-section along the thinnest side (2 mm) were generated every 100 
µm using a spectral confocal laser scanning microscope digital imaging system (Leica 




4.2.6 Ultra Structure – Scanning Electron Microscopy 
Samples were fixed  (2% PFA and 1.25% glutaraldehyde in 0.1 M sodium cacodylate 
(CAC) buffer, pH 7.4) for 1hr at room temperature and transferred to buffer (3% 
glutaraldehyde in 0.1 M CAC buffer, pH 7.4) for 30 min.  Samples were rinsed with 
washing buffer (5% sucrose, 0.1 M CAC buffer, pH 7.4), post-fixative buffer (1% 
osmium tetroxide in 0.1 M CAC buffer, pH 7.4) and water, serially dehydrated, 
critical point dried, and sputter coated with gold.  They were observed with a 
scanning electron microscope at 15 kVP (Quanta 200, FEI Company, Hillsboro, OR). 
4.2.7 Collagen deposition – Sirius Red 
Constructs were digested with 500 µl of pepsin solution (0.25 mg/ml), and stained 
with Sirius red collagen detection kit (Chondrex, Redmond, WA) according to the 
manufacturer’s instructions.  Absorbance was read at 540 nm using a microplate 
reader (Biotek, Winooski, VT).  Values were normalized to scaffold only.  The 
collagen in each sample was extrapolated from a standard curve provided with the kit. 
4.2.8 Procollagen Synthesis – Procollagen I N-terminal Peptide (PINP) Enzyme 
Linked Immunosorbant Assay (ELISA) 
Concentration of procollagen I N-terminal peptide (PINP) was measured in medium 
when medium was changed every 7 days.  Media were collected from each chamber 
and the reservoir.  Samples were stored at -80°C, thawed on ice and thoroughly mixed 
before using.  PINP levels were measured using the canine PINP ELISA kit (Biotang, 
Framingham, MA) according to manufacturer’s instructions.  Absorbance at a 
wavelength of 450 nm was measured.  Concentrations were determined from a 
standard curve provided with the kit.  Concentrations in the results reflected the PINP 




4.2.9 Target Gene Expression - qRT-PCR (quantitative reverse transcription-
polymerase chain reaction) mRNA levels  
Constructs were rinsed with PBS, and homogenized (TissueLyser II, Qiagen, 
Valencia, California, USA) in TRIzol reagent (Sigma).  Total RNA was extracted by 
phenol-chloroform extraction according to TRIzol reagent’s instructions.  Quantity 
was determined with a ND-100 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE), and only samples with an A260/A280 ratio higher than 1.7 were 
used.  mRNA was reverse transcribed into cDNA using a QuantiTect Reverse 
Transcription Kit (Qiagen, Hilden, Germany).  Canine-specific primers against 
collagen I (col1), collagen III (col3), biglycan (BGN), decorin (DCN), tenascin-c 
(TCN), fibronectin (FN) and tenomodulin (TNMD) were designed using Primer3 and 
annotation databases available at the University of California, Santa Cruz (UCSC) 
Genome Browser database (http://genome.ucsc.edu/) (Table 14).  qRT-PCR was 
performed in duplicate using a QuantiTect SYBR Green PCR Kit (Qiagen) in a 384 
well PCR plate.  PCR amplification was performed using Applied BioSystems 7900 
Real-Time PCR System (SDS v2.4; Applied Biosystems, Carlsbad, CA).  In the 
present study, the data was normalized to GAPDH, and presented as the fold change 
in target gene expression relative to the stromal control according to 2-ΔΔCt [176].   
4.2.10 Statistical analysis 
Values are presented as mean ± SEM. Two-way ANOVA models were applied to 
determine effects of culture time and induction medium on cell metabolic activities, 
collagen deposition and procollagen synthesis with Tukey’s post-hoc tests.  One-way 






Table 13 Canine-specific primer sequences for ligament differentiation 
 Forward Primer Reverse Primer 
GAPDH TGGCAAAGTGGATATTGTCG AGATGGACTTCCCGTTGATG 
Col1 CTATGACCGAGACGTATGGA GTTTCTTGGTCGGTAGGTGAC 
Col3 CAGAGATCCCATTTGGAG CATTTCTCCCAGGAATACC 
BGN CCACAACCAGATCCGCATGAT AGAAGTCGTTGACGCCCAC 
DCN CTCTAGCCAACACTCCTCAT GGCAGAAGTCATTAGATCCG 
TNC CCACAATGGCAGATCCTTC CCTTCCAGTGGAACCAGTTA 
FN GGTTTGTACCTGTTACGGAG CAGATCATGGAGTCCTTAGG 
TNMD CCAGCAGAAAAGCCTATTG GACCACCCACTGCTCGTTT 
4.3 Results 
4.3.1 PLLA: PEG scaffold construction 
A CrCL structure mold was successfully printed (Figure 14A).  However, during 
polymer injection, the mold split and polymers leaked during freezing.  Further 
modifications were made with two columns by both sides, one for injecting materials 
and the other for air ventilation (See B-D in Figure 14).  The outside structure of 
PLLA: PEG scaffold was similar to the native CrCL, and the inside pores were 44 x 
22 µm2 (See A, B in Figure 14).  
4.3.2 Loading Efficiency  
The loading efficiency for the PLLA: PEG scaffold in stromal medium was 83% 
(Figure 15).  With fibronection coating, collagen scaffold had significantly higher 
loading efficiency than non-coated groups.  No significant changes were shown using 





Figure 14 PLLA: PEG scaffold 
The 3D prototype was printed using acrylonitrile butadiene styrene (ABS) (A), and 
modified with columns (B,D).  Rhinoceros 4.0 prototype C (C).  
 
 
Figure 15 Loading efficiency (mean ± SEM, n=3) 
PLLA: PEG and collagen scaffolds were loaded in stromal medium or ligament 
induction medium for 2 hrs with or without coating with fibronection (Fn).  Needs 
more description.  What is shown here? 
4.3.3 SEM Images of PLLA: PEG Scaffold Cultured in PRP and stromal media 
The construct cultured with 10% PRP was fully covered with platelets after 21 days of 
culture (See C in Figure 16).  Cells were also evident in scaffolds cultured in other 
media, 1% PRP (See D in Figure 16), 0.1% PRP (See E in Figure 16) and stromal 
medium (See F in Figure 16).  However, the scaffold failed to maintain the structure 


























































Figure 16 Scanning electron photomicrograph of PLLA: PEG scaffold 
The outside was similar to native CrCL (A), and the inside was porous (B).   The 
scaffold was covered with platelets (red arrows) following culture in 10% PRP 
medium (C).  The IFP ASCs (red arrows) were attached to the surface of the scaffold 
in 1% PRP medium (D), 0.1% PRP medium (E) and stromal medium (F).   
4.3.4 Cytotoxicity of ZnCl2 Medium 
After 4 hrs incubation, monolayer cells did not show significant toxicity effects with 
up to 20 µM ZnCl2 (See A in Figure 17).  No significant differences were found in 
metabolic activities of biopsy samples from different locations.  Therefore, data were 
combined for further analysis.  There was no significant change of cell metabolic 
activities between zinc and stromal medium immediately after loading (See B in 
Figure 17).  However, medium became acidic with a pH of 4.2 after 7 days of culture, 
and the majority of cells were dead (See C,D in Figure 17).  Additonally, scaffolds 
had significantly lower metabolic activities after 7 days culture in medium with zinc 
than 2hr after loading (See B in Figure 17).  In contrast, after 7 days of culture in 
stromal medium, cells on the collagen scaffold had significantly higher metabolic 





Figure 17 Cytotoxicity of ZnCl2 
Cells were cultured in stromal medium with different concentrations of ZnCl2 
overnight and then stained with Alamar Blue for 4hr (A). Cells were loaded onto the 
collagen scaffold, and metabolic activity (mean ± SEM, n=3) was measured 
immediately after loading and 7 days (B).  Construct was stained with calcein (green) 
and ethidium bromise (red) and observed with fluorescent and (5x) (C) and confocal 
laser microscopy (20x) (D).  Columns with different letters are significantly different 
from stromal control (P < 0.05).  Columns with asterisks are significantly different 
from 0d.   
4.3.5 Growth Factor Medium  
When collagen scaffolds were coated with Fn, the metabolic activity was significantly 
higher than non-coated controls (See A in Figure 18).  There were more cells apparent 
with viability staining and confocal laser microscopy (See B in Figure 18).  Based on 
these results, COLI scaffolds were first incubated with Fn for 30 min before loading.  
Additionally, no significant differences were found among biopsy samples from 
different locations of the construct (1, 2, 3 cm from the top of the template), so data 
were combined.   
 No significant differences were found in cell metabolic activity between 
growth factor and stromal medium up to 21 days (See A in Figure 19).  There was 




cells were larger (See B in Figure 19).  After 21 days of culture, more cells were 
apparent in confocal laser and scanning electron images (Figures 20, 21), and 
constructs had significantly higher activity than 7 and 14 days (See A in Figure 19).   
 
Figure 18 Metabolic activity (mean ± SEM, n=6) of construct with Fn coating for cell 
loading 
Collagen scaffolds were soaked in Fn solution for 30 min before loading.  After 2 hrs, 
metabolic activity was measured for both Fn and control group.  Samples were stained 
with calcein (green) and EB (red), and observed by confocal microscope. 
 
Figure 19 Metabolic activity (mean ± SEM, n=5) of canine ASC–COLI constructs  
Canine ASC-COLI constructs were cultured in a perfusion bioreactor up to 21 days.  
Metabolic activity was measured after 0, 7, 14 and 21 days of culture in 
ligamentogenesis or stromal medium. 
4.3.6 Collagen Deposition 
Since Sirius red stains the collagen, staining was normalized to scaffold only (cultured 
for the same period of time).  Constructs in ligamentogenesis medium had higher 
collagen than those cultured in stromal medium after 21 days of culture (Figure 22).  




group, and collagen content was significantly greater in both groups after 21 days of 
culture compared to 7 days. 
 
Figure 20 Confocal images of canine ASC-COLI constructs 
Constructs were cultured in stromal (A-D) or ligamentogenesis (E-H) medium up to 
21 days.  Samples were collected after 7 (B,E), 14 (C,F) and 21 (D,G) days of culture.  
Samples were stained with calcein (green, viable) and ethidium bromide (red, 




Figure 21 SEM images of canine ASC-COLI constructs 
The ASCs (red arrows) – COLI constructs were cultured in ligamentogenesis (B-D) or 
stromal (E-G) medium up to 21 days.  Samples were collected after 7 (B,E), 14 (C,F) 






Figure 22 Total collagen content (mean ± SEM, n=6) of canine ASC-COLI constructs 
cultured in stromal or ligamentogenesis medium for 7, 14 or 21 days.   
Scaffold was digested with pepsin and total collagen deposition was measured, 
normalized to scaffold only, and determined on a standard curve.  Columns with 
different letters are significantly different from other time points within treatment 
cohorts (P < 0.05).  Columns with asterisks are significantly different from stromal 
control within time points.   
4.3.7 Pro-collagen Synthesis 
The medium PINP levels were significantly higher in medium surrounding constructs 
cultured in ligamentogenesis medium versus those in stromal medium after 7 and 
21days of culture (Figure 23).  Within cohorts, levels were significantly higher in the 
ligamentogenesis medium group after 21 versus 7 and 14 days of culture, and in the 
stromal medium group after 21 and 14 days versus 7 and 14 days of culture.   
 
Figure 23 Pro-collagen synthesis (mean ± SEM, n=4) of canine ASC/ColI scaffold 
construct 
Medium was collected at day 7, 14 and 21 after loading.  Concentration of PINP was 
measured using an ELISA kit.  Columns with different letters are significantly 
different from other time points within treatment cohorts (P < 0.05).  Columns with 



















































4.3.8 Ligamentogenesis Target Gene Expression 
In general, constructs cultured in ligamentogenesis medium had higher mRNA levels 
of COLI, COLIII, TNMD, FN TNC, BGN and DCN than those cultured in stromal 
medium (Figure 25).  Additionally, mRNA levels of the genes were highest after 21 
days of induction, followed by 14 and 7 days.  The col1, TNC and TNMD expression 
was significantly higher at day 21 compared to day 7. 
 
Figure 24  Fold change (mean ± SEM, n=4) of ligament target gene mRNA levels in 
canine ASC/ColI scaffold constructs  
Fold change of mRNA levels in the constructs cultured in ligament induction medium 
relative to those in stromal medium for 7, 14 or 21 days.  Columns with different 
letters are significantly different from each other (P < 0.05).  
4.4 Discussion 
The ideal regenerated tissue will have cell proliferation, protein synthesis, deposition 
of ECX and mechanical properties similar to the native tissue.  Consistent with the 
hypothesis, the collagen type I porous scaffold with PDS II suture supported IFP ASC 
attachment, proliferation, ligament differentiation and collagen deposition when 
cultured in ligamentogenosous induction medium. 
The IFP was used as the MSC source in this study.  Different cell sources have 
been used in ligament tissue engineering such as MSCs and fibroblasts [330-333].  
Previous work in the laboratory confirmed that, up to P3, MSCs from the IFP have 








































compared to those from joint capsular and CrCL synovium [233].  Other studies have 
shown that rabbit BMSCs from iliac crest have higher proliferation and collagen 
excretion than ACL and MCL fibroblasts [118].  Since orthotopic MSCs generally 
have higher potential for tissue-specific cell differentiation than heterotopic cells, IFP 
ASCs may be an optimal cell source for ACL tissue regeneration [167].  To optimize 
cell attachment, the scaffold was coated with fibronection [140].  A relatively low cell 
seeding density was used since the ACL is relatively hypocellular compared to other 
tissues [334]. 
The scaffold material selection is also critical to provide similar physical and 
mechanical properties, degradability, and structural integrity similar to the original 
CrCL.  The ideal pore diameter for soft tissue formation is around 200 – 250 µm [124].  
Both PLLA and PGA are biocompatible materials approved by the FDA for clinical 
applications [308, 309].  Both have been applied for ligament engineering with 
promising short-term.  However, in this study, these materials failed to maintain their 
structure during long-time dynamic culture.  Previous studies have also shown poor 
tissue integration, poor abrasion resistance and fatigue on long-term impact [335, 336].  
Further modifications in relative ratios and construct structure may help resolve some 
of the problems observed [308].   
Type I collagen is the major component of the CrCL. The scaffold used in this 
study is commercially available and has been applied in orthopedic tissue 
regeneration [316].  It possesses interconnected pores with an average diameter of 190 
µm [337].  However, collagen alone is not durable enough for long-term application 
[317, 318].  Compared to other absorbable sutures, PDS II has relatively higher tensile 
strength and failure load [338].  Therefore, a PDS suture was used to constructs the 




confer mechanical strength and durability to the scaffold. The template was  also 
constructed with implantation in mind.  Since the structure must be secured to the 
tibia and femur within bone tunnels, the construct has elongated suture ends covered 
with COLI and ASCs to secure the graft and facilitate integration into bone.   
 Perfusion bioreactors have been shown to improve the efficiency of 3D tissue 
engineering [334].  The custom-made chamber allowed homogenous cell distribution 
and maintenance of the scaffold with a 45-degree turn at the midpoint.  Different fluid 
flow rates have been applied in perfusion bioreactors.  Very-low flow rates (0.01 
ml/min) have been used to achieve low shear stress and high cell viability [144, 339].  
In contrast, high flow rates result in lower cell viability [334].  To provide optimal 
distribution of cells, nutrients, oxygen and removal of wastes for orthopedic 
applications, a fluid flow range from 0.2 to 1 ml/min has been suggested [334].  
According to Haagen-Poisseuille equation, τ = 32µQ/πd3 (τ: shear stress; Q: flow rate; 
d: diameter; µ: kinetic viscosity), shear stress is directly proportional to flow rate and 
inversely proportional to vessel diameter [340].  Considering the relatively large 
volume of the system, this study used the flow rate at 1 ml/min. 
 Though the exact cocktail to differentiate MSCs into ligament fibroblasts still 
has yet to determined, several chemicals and growth factors have been identified.  
Platelet-rich plasma has been widely applied for in vivo intraarticular CrCL repair and 
regeneration [341].  However, high concentrations (10%) of PRP interfered with ASC 
attachment to scaffold in this study based on the size of particles (3µm) in SEM 
images.  Zinc promotes ligamentous healing, and has been reported to stimulate MSC 
proliferation and DNA synthesis [342].  However, in this study, it significantly 
induced pH reduction and cell death at low concentrations.  The results are consistent 




βFGF, TGFβ, PDGF, VEGF and IGF are reported to induce ligamentogenesis [344-
346].  A combination of βFGF and TGFβ were previously reported to induce 
significantly higher COLI deposition and tissue strength through matrix synthesis in 
human BMSCs than other formulations in vitro [345].  Previous studies also found 
that TGFβ and PDGF cultured with rabbit BMSCs were in high concentrations during 
the initial phases of CrCL healing, and were crucial for neo-tissue formation and 
restoration of function both in vitro and in vivo [346, 347].  Lower serum was applied 
in the induction medium since it achieved significant increase of COLI mRNA levels 
compared to the stromal medium in vitro [345].  The medium described in this study 
appeared to generate significant higher ligamentogenesis based on target gene 
expression, collagen deposition and pro-collagen synthesis.  The medium may prove 
useful to generate viable grafts in vitro. 
 The mRNA data from this study suggests that constructs cultured in induction 
medium had increased ligament target gene expression.  Although there is no single 
specific gene for ligamentogenesis, col I, col III, TNMD, TNC, BGN, DCN and FN 
are all expressed in normal and healing CrCL [348-352].  Early stage markers, TNMD 
and TNC, are necessary for cell proliferation and collagen fibril maturation [353, 354].  
Collagen II and proteoglycans like BGN and DCN regulate assembly of collagen 
fibrils at later stages of ligament development or repair [355-357].  Additionally, the 
upregulation of TNC suggests ligament being mechanically stimulated, indicating 
successful mechanical stimulation provided in the perfusion bioreactor [358].  The 
significant increase of col I, TNMD and TNC with no change in col III, BGN and 
DCN in this study is more consistent with a pattern of early stage ligament 




 Regenerated tissues with MSCs have advantages over traditional therapies.  
The MSCs from healthy and young donors may have advantages of generating neo-
tissue as well as immunoregulatory effects, since the number and differentiation 
potential of MSCs are interfered by diseased or aged conditions [51, 104, 167].  The 
MSCs would not only differentiate into tissue-specific lineages, but also attract 
bioactive factors to accelerate healing process without stimulating the host immune 
response.  This study designed a specific perfusion bioreactor system to regenerate a 
viable canine CrCL graft with the native structure.  Further MSC sorting with MSC 
and immunogenic surface markers may generate a purer population that can be further 
applied to grow the CrCL.  Longer in vitro culture time in the induction medium may 
also help ligamentogenesis and maturation of MSCs.  Additional studies should 
include comparisons of CrCLs generated from ligamentogenesis or stromal medium 
in rodent models.  Even though this in vitro study cannot reflect in vivo characteristics 
of the CrCL, it provides vital translational information of MSC in tissue engineering 














CHAPTER 5. CONCLUSIONS AND FURTHER STUDIES 
This dissertation is focused on translational studies of adult multipotent stromal cells 
(MSCs).  Overall, MSC-mediated therapies are in the early stage of development.  
Due to their apparent versatility, MSCs have been applied in over 100 human clinical 
trials to treat various diseases and conditions.  Unfortunately, results have been 
inconsistent and, in some cases, less than favorable..  It is clear that controlled 
investigations are necessary in the field of adult MSCs.  The International Society for 
Cellular Therapy position has minimal standards to define human MSCs.   A standard 
definition of adult MSC in veterinary medicine is also needed.  However, limited 
technical resources like species-specific antibodies make this goal challenging.  Major 
contributions of the studies described in this dissertation are species specific 
techniques to isolate and characterize canine and feline MSCs.  
 An efficient adipose derived multipotent stromal cell (ASC) isolation 
technique was developed for the feline study.  Using the technique, ASCs can be 
harvested from limited tissue to avoid the need for significant tissue harvest from   
one animal or to combine tissues from several animals.  Use of tissues from one 
animal may also lower risk of rejection.  Feline-specific induction medium was 
designed and tested to confirm feline MSC multi-potentiality and to be used in future 
feline tissue regeneration studies.  Results of the study showed that feline ASCs are 
only suitable for treatment or tissue engineering up to 3 passages in vitro.  Evaluation 
of the effects of cryopreservation showed that feline ASCs could be banked without 
losing their expansion and differentiation capabilities.  The MSC surface markers that 
were validated in the study can be used to select MSCs from a heterogenous cell 




The results from the canine intra-articular MSC study showed that adipose-
derived MSCs (ASCs) have the most promise for intraarticular application.  Tissues 
evaluated in the study are the three most popular MSC sources inside the stifle and the 
results will be of interest to both surgeons and scientists.  Considering IFP tissue is 
often excised during stifle surgeries, it is a reasonable choice for cell isolation that 
will not require specific tissue harvest.  It is also possible that ASCs from IFP tissues 
may be protected from intra-articular inflammation.  The fact that ASCs maintain 
their properties after cryopreservation may make it possible to use allogeneic ASCs 
from normal stifle joints.  The MSC phenotype was confirmed in this study and the 
techniques can be used for unrelated canine MSC studies to benefit research and 
clinical application.   
The third part of this describes use of canine IFP ASCs, to regenerate cranial 
cruciate ligament (CrCL) neotissues.  It is possible that the viable structures can be 
matured into grafts for clinical application or may serve as a template to promote 
CrCL generation in vivo.  The scaffold template may support both approaches to 
CrCL repair.  For the study, custom scaffold templates were designed, 
ligamentogenesis medium optimized for canine ACS ligament induction and a novel 
bioreactor seeding and culture system designed and applied to grow constructs up to 
21 days.  Progressive tissue maturation was confirmed at various time points during 
the culture period.  Implantation of induced cells may have significant advantages 
over naïve MSCs.  This work is highly novel and may benefit both canine and human 
patients that suffer from rupture of the major ligament in the stifle (knee) joint. 
This dissertation provides critical information to translate MSC from the 
laboratory to clinical application.  Further studies may include purification of feline 




generated in vitro, further maturation of CrCL with longer culture time and MSC 
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